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1Ensuring Balance in National Policies on Controlled Substances 
PrEfacE
The international drug control treaties came into being to prevent the abuse of substances that can induce 
dependence. The universal adoption of the treaties and their implementation continue to be highly effective 
in preventing the diversion of drugs from licit to illicit markets in international trade and in protecting 
society from the consequences of dependence. However, equal emphasis has not been placed on the other 
fundamental objective of the treaties of ensuring that controlled substances are available for medical and 
scientific purposes. As a result, the health benefits that can be derived from medicines containing controlled 
substances remain inaccessible to the large majority of people around the world.
The majority of substances controlled under the international drug control treaties, notably narcotic 
drugs and psychotropic substances, have a variety of medical uses. Opioid analgesics, such as codeine and 
morphine, and antiepileptics, such as lorazepam and phenobarbital, are considered as essential medicines 
by the World Health Organization. There is broad consensus that opioid analgesics are indispensable for the 
treatment of moderate to severe pain and some, like methadone and buprenorphine, are increasingly used 
for the treatment of drug dependence. The widespread recognition of the therapeutic value of controlled 
substances has led in recent years to a substantial increase in their consumption. However, this increase 
has occurred predominantly in developed countries. In contrast, the availability of controlled substances 
has remained very low in most developing countries and is far from adequate to meet the medical needs 
of their populations. Unless remedial measures are implemented, the gap in the availability of controlled 
substances, namely opioid analgesics, will widen as the number of patients diagnosed with cancer and AIDS 
in developing countries rises. 
There are many reasons to account for the inadequate availability of controlled substances for medical 
purposes. Some relate to the economic and social development of a country and affect the supply of 
medicines in general. Others are specific to controlled substances and operate within the specific regulatory 
system that exists in some countries for the manufacture, prescription and distribution of such substances. 
In some countries, laws and regulations intended to prevent the misuse of controlled substances are overly 
restrictive and impede patient access to medical treatment with such substances. Such situations can arise 
when insufficient attention is paid to the impact of regulations on the supply of controlled substances for 
medical purposes. Yet preventing the abuse of controlled substances and ensuring their availability for licit 
uses are complementary, and not mutually exclusive, objectives of the international drug control treaties. 
An effective drug control regime that complies with the spirit of the drug control treaties should therefore 
strike the right balance between the considerations given to these two aims. 
Undue regulatory restrictions often have their origins in poor understanding among policy makers about 
controlled substances and their therapeutic value. Moreover, in many countries, inadequate knowledge 
and fear of dependence are key reasons behind the unwillingness of health professionals to prescribe 
controlled substances. To address these issues, policy makers need to go a step further than relaxing 
regulatory restrictions to availability: they should devise and implement enabling policies that promote 
widespread understanding about the therapeutic usefulness of controlled substances and their rational 
use. Health professionals should be trained in prescribing and administering controlled substances. 
Patients should be informed about the benefits and risks of using controlled substances. Drug control 
and law enforcement personnel should be sensitized to their medical and scientific necessity. Promoting 
dialogue among all these sectors is also essential to foster understanding and dispel misconceptions about 
the medical use of controlled substances. Furthermore, it is by integrating the concerns of all sectors that 
influence the use of controlled substances that policies can achieve the optimal balance between ensuring 
access and preventing abuse. 
2Ensuring that controlled medicines reach those patients who need them most is a multifaceted challenge. 
As such, it demands a response that is applied on many fronts and that requires the involvement of 
and cooperation among many sectors of Government and society. This response should be rooted in the 
recognition that controlled substances are indispensable for medical and scientific purposes. This recognition 
means that ensuring access to controlled substances should be given due importance on the public health 
agenda of countries. This recognition should also be at the source of the strong and sustained support that 
all Governments must provide to the complex task of removing impediments to the availability of controlled 
medicines and promoting their rational use.
Ensuring the adequate availability of controlled substances for medical and scientific purposes is one of 
the objectives of the international drug control treaties that has yet to be universally achieved. As the 
guardian of the international drug control treaties, the International Narcotics Control Board (INCB) has 
often called upon Governments to give to this treaty objective the attention that it deserves in their drug 
control policies. It is to assist Governments in this task that WHO, with the support of INCB, developed the 
first version of the present guidelines ten years ago. Today, controlled substances continue to be important 
for the relief from pain and suffering and have been recognised to be essential for treating some of the most 
debilitating diseases and conditions that afflict our societies. It is therefore more than ever an imperative to 
achieve a balance in controlled substances policies so that these work to protect societies from the misuse of 
controlled substances without depriving them from their immense medical and scientific benefits. 
Hamid Ghodse
President
International Narcotics Control Board 
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forEWord
These new World Health Organization (WHO) policy guidelines Ensuring balance in national policies on 
controlled substances: guidance for availability and accessibility of controlled medicines build on a previous 
set of guidelines, Achieving balance in national opioids control policy: guidelines for assessment, published 
in 2000. 
The 2000 document primarily addressed the need to address pain in cancer patients. However, WHO 
estimates that every year 5.5 million terminal cancer patients still suffer moderate to severe pain that is not 
managed at all. There is therefore a continued need for guidance in this area.
Cancer, however, is not the only cause of pain. WHO estimates that tens of millions of people experience 
unrelieved pain from different diseases and conditions other than cancer, and therefore require access to 
medicines (many of which are controlled) to relieve pain. 
And controlled medicines are not only used to relieve pain. Better access to different controlled medicines 
could prevent for instance 130 000 new HIV infections among injecting drug users, and around 75 000 cases 
of maternal death.
The new guidelines cover a wider range of medicines and signal aspects that were previously not covered, but 
that should be considered while working on improving access: human rights, gender and the public health 
perspective. 
The challenge now is to implement them. WHO commits to helping countries use the guidelines, assisting 
them in carrying out assessments of legislation and policies and assisting in strategies to overcome the 
current barriers for access. 
Dr Carissa F. Etienne
Assistant Director-General
Health Systems and Services
World Health Organization
4EXEcutivE summary
Ensuring balance in national policies on controlled substances: guidance for availability and accessibility of 
controlled medicines provides guidance on policies and legislation with regards to availability, accessibility, 
affordability and control of medicines made from substances regulated under the international drug control 
conventions, herein referred to as “controlled medicines”. Their scope encompasses “all controlled medicines”, 
but with a specific focus on essential medicines. Controlled medicines play an important role in several areas 
of medicine, including pain treatment, treatment of opioid dependence, emergency obstetrics, psychiatry and 
neurology.
The availability, accessibility and affordability of controlled medicines are important issues for all countries, 
but problematic for most of them. The World Health Organization (WHO) promotes governments, civil society 
and other interested individuals to strive for the maximum public health outcome of policies related to 
these medicines. WHO considers the public health outcome to be at its maximum (or “balanced”) when the 
optimum is reached between maximizing access for rational medical use and minimizing substance abuse. 
Policy-makers, academia, civil society and other individuals whose area of work or interest is drug control 
or public health may potentially work with these guidelines in order to ensure that better use is made of 
controlled medicines and that more patients benefit from the advantages that their rational use can offer.
All countries have a dual obligation with regard to these medicines based on legal, political, public health 
and moral grounds. The dual obligation is to ensure that these substances are available for medical purposes 
and to protect populations against abuse and dependence. Countries should aim at a policy that ultimately 
achieves both objectives; in other words, a “balanced policy”.
The core legal basis for this obligation can be found in the international drug control conventions. Legal 
principles supporting national responsibility to ensure availability for medicinal purposes is also expressed in 
several legal instruments elaborating the international right to health. The political grounds can be found 
in various Millennium Development Goals, which cannot be achieved without controlled medicines. From 
the public health perspective, there are many societal benefits, including cost savings and reduction of 
transmission of infectious disease. Obviously, there is a moral obligation on governments to prevent people 
from suffering or dying if this is in any way preventable. 
However, WHO estimates that every year tens of millions of people suffer disease, moderate to severe pain 
and ultimately death due to not having access to controlled medicines, including:
•	 1 million end-stage HIV/AIDS patients;
•	 5.5 million terminal cancer patients;
•	 0.8 million patients suffering injuries caused by accidents or violence;
•	 Patients with chronic illnesses;
•	 Patients recovering from surgery; 
•	 Women in labour (110 million births each year);
•	 Paediatric patients;
•	 130 000 preventable new HIV infections and an unknown number of other blood-borne infections;
•	 75 000 women who die during childbirth. 
After 1986, the total global consumption of morphine increased significantly, but the increase only occurred 
in a limited number of industrialized countries. Approximately 80% of the world’s population does not 
have access to morphine for pain relief. For the pharmacological treatment of dependence syndrome, only 
70 countries have services that are operational, while globally only 8% of injecting drug users receive this 
therapy.
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Controlled medicines may be unavailable, inaccessible or unaffordable for a variety of reasons, including:
•	 legislation and policy issues;
•	 lack of knowledge and societal attitude;
•	 economic aspects.
Governments should therefore work continuously on all of these aspects in order to make controlled 
medicines available, accessible and affordable.
This document provides 21 guidelines for working on the improvement of availability, accessibility and 
affordability of controlled medicines from a policy perspective. They relate to seven aspects of policy and 
legislation:
•	 content of drug control legislation and policy (Guidelines 1 and 2);
•	 authorities and their role in the system (Guidelines 3 to 6);
•	 policy planning for availability and accessibility (Guidelines 7 to 10);
•	 healthcare professionals (Guidelines 11 to 14);
•	 estimates and statistics (Guidelines 15 to 17);
•	 procurement (Guidelines 18 to 20);
•	 other (Guideline 21).
For each guideline, an explanation is provided, as well as the legal background and/or justification for the 
guideline. A Country Assessment Checklist is also provided that enables users of the guidelines to check the 
extent to which they are adhered to in a particular country.
The guidelines may be used by governments, health professionals and others as a national policy and 
legislation evaluation tool, by providing a basis for formulating new policies and legislation or improving 
existing policies and legislation; they may also be used as an educational tool to inform interested parties 
about the relationship between national drug control policy and legislation and the availability and 
accessibility of controlled medicines. Countries who wish to formulate new policy in this area, or improve 
existing policies and legislation may also want to work with WHO’s Access to Controlled Medications 
Programme (ACMP). The ACMP was jointly developed by the International Narcotics Control Board (INCB) 
and WHO, and is operated by WHO. 
This publication also includes several annexes and a CD-ROM that provide additional documentation. 
The use of these guidelines and the Country Assessment Checklist may enable governments to systematically 
identify and assess policy barriers, and gradually progress towards a situation where controlled medicines are 
both readily available and accessible. 
With the publication of this document, the previous guidelines Achieving balance in national opioids control 
policy: guidelines for assessment (2000) are withdrawn.
6Glossary a
Abuse is defined by the WHO Expert Committee on Drug Dependence as “persistent or sporadic excessive 
drug use inconsistent with or unrelated to acceptable medical practice” (1). Abuse of a substance is a term 
in wide use but of varying meaning. The term “abuse” is sometimes used disapprovingly to refer to any drug 
use at all, particularly of illicit drugs. Because of its ambiguity, “abuse” is not used in ICD-10, except in the 
case of non-dependence-producing substances; harmful use and hazardous use are the equivalent terms 
in WHO usage, although they usually relate only to effects on health and not to social consequences (2). 
The international drug conventions use the word “abuse” and not “misuse” or “harmful and hazardous use”; 
therefore, these guidelines use this word frequently, in particular when in relation to the conventions or their 
objectives. 
Accessibility is the degree to which a medicine is obtainable for those who need it at the moment of need 
with the least possible regulatory, social or psychological barriers.
Affordability is the degree to which a medicine is obtainable for those who need it at the moment of need 
at a cost that does not expose them to the risk of serious negative consequences such as not being able to 
satisfy other basic human needs.
Agonist is a substance that binds to a receptor of a cell and triggers a response by that cell. Agonists often 
mimic the action of a naturally occurring substance. 
Analgesic is a medicine that reduces pain.
Antagonist is a substance that blocks the action of an agonist.
Availability is the degree to which a medicine is present at distribution points in a defined area for the 
population living in that area at the moment of need.
Consumption statistics have to be reported by governments to the International Narcotics Control Board 
(INCB) annually and represent the amounts of narcotic drugs that were distributed in the country to the 
retail level, i.e. to hospitals, pharmacies and practitioners.
Controlled medicines are medicines containing controlled substances. 
Controlled substances are the substances listed in the international drug control conventions. 
Convention is a formal agreement between States. The generic term “convention” is thus synonymous with 
the generic term “treaty”. Conventions are normally open for participation by the international community 
as a whole, or by a large number of States. Usually the instruments negotiated under the auspices of an 
international organization are entitled conventions (3, 4).
Defined Daily Dose (DDD) is the assumed average maintenance dose per day for a medicine used on its 
main indication in adults (5).
Dependence is defined by the WHO Expert Committee on Drug Dependence as “A cluster of physiological, 
behavioural and cognitive phenomena of variable intensity, in which the use of a psychoactive drug (or 
a References to this guidelines document can be found on the CD-ROM and on the internet at www.who.int/entity/medicines/areas/
quality_safety/ReferencesEnsBal.pdf 
7Ensuring Balance in National Policies on Controlled Substances 
drugs) takes on a high priority. The necessary descriptive characteristics are preoccupation with a desire to 
obtain and take the drug and persistent drug-seeking behavior. Determinants and problematic consequences 
of drug dependence may be biological, psychological or social, and usually interact” (6). Dependence is 
clearly established to be a disorder. WHO’s International classification of diseases, 10th Edition (ICD-10) (7) 
requires for Dependence syndrome that three or more of the following six characteristic features have been 
experienced or exhibited:
(a) a strong desire or sense of compulsion to take the substance;
(b) difficulties in controlling substance-taking behaviour in terms of its onset, termination, or levels 
of use;
(c) a physiological withdrawal state when substance use has ceased or been reduced, as evidenced 
by: the characteristic withdrawal syndrome for the substance; or use of the same (or a closely 
related) substance with the intention of relieving or avoiding withdrawal symptoms;
(d) evidence of tolerance, such that increased doses of the psychoactive substance are required in 
order to achieve effects originally produced by lower doses;
(e) progressive neglect of alternative pleasures or interests because of psychoactive substance 
use, increased amount of time necessary to obtain or take the substance or to recover from its 
effects;
(f) persisting with substance use despite clear evidence of overtly harmful consequences, such as 
harm to the liver through excessive drinking, depressive mood states consequent to periods of 
heavy substance use, or drug-related impairment of cognitive functioning; efforts should be 
made to determine that the user was actually, or could be expected to be, aware of the nature 
and extent of the harm.
The Expert Committee on Drug Dependence (ECDD) concluded that “there were no substantial inconsistencies 
between the definitions of dependence by the ECDD and the definition of dependence syndrome by the ICD-
10” (6).
Diversion refers to the movement of controlled drugs from licit to illicit distribution channels or to illicit use.
Essential medicines (for children) are those medicines that are listed on the WHO Model List of Essential 
Medicines or the WHO Model List of Essential Medicines for Children. Both model lists present a list of 
minimum medicine needs for a basic healthcare system, listing the most efficacious, safe and cost-effective 
medicines for priority conditions. Annex 1 provides a list of controlled medicines also included on these Lists.
Estimates of the requirements for controlled substances for legitimate purposes have to be submitted to 
INCB by the national competent authority. For narcotic drugs and for certain precursor chemicals, estimates 
have to be submitted to INCB annually and for psychotropic substances, simplified estimates (known as 
assessments) have to be submitted at least every three years.
International drug control conventions are the Single Convention on Narcotic Drugs of 1961 as amended 
by the 1972 Protocol, the Convention on Psychotropic Substances of 1971, and the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988.
Law refers to a set of rules on a specific topic enacted by the legislative body at the national, state or local 
level and having binding legal force.
Legislation refers to all rules having binding legal force at the national, state or local level. 
Maintenance therapy (or opioid substitution therapy) with long-acting opioid agonists for the treatment 
of opioid dependence involves relatively stable doses of the agonists (usually methadone or buprenorphine) 
prescribed over prolonged periods of time (usually more than six months), which allows stabilization of brain 
functions and prevention of craving and withdrawal (8).
8Misuse (of a controlled substance) for the purposes of these guidelines, is defined as the non-medical and 
non-scientific use of substances controlled under the international drug control treaties or under national law. 
Narcotic drugs is a legal term that refers to all those substances listed in the Single Convention.
National authority, in these guidelines, refers to any government institution involved with the issues 
discussed in this document. The term applies not just to national government institutions but may equally 
apply to other relevant institutions in the national territory involved with these issues, such as federal, state 
or provincial institutions.
National competent authority, in these guidelines, refers to any government agency responsible under 
its national law for the control or regulation of a particular aspect of the country’s controlled substances 
legislation, in particular to issue certificates and authorizations for the import and export of narcotic drugs 
and psychotropic substances (9).
Opioid means literally “opium-like substance”. It can be used in different contexts with different but 
overlapping meanings:
1. Botanical: chemical substances belonging to the class of alkaloids produced by the poppy plant (Papaver 
somniferum L.). They can also be called natural opioids. Some of them (e.g. morphine and codeine) have 
analgesic properties (“pain killers”); others do not.
2. Chemical: chemical substances having similar structural formulas as morphine, codeine and other natural 
opioids (the benzylisoquinoline structure). They may be natural or synthetic. An example of a (semi-)synthetic 
opioid is buprenorphine. 
3. Pharmacological: chemical substances having similar pharmacological activity as morphine and codeine, 
i.e. analgesic properties. They can stem from the poppy plant, be synthetic or even made by the body itself 
(endorphins), and they may be structurally related to morphine or not. An example of a synthetic opioid not 
structurally related to morphine is methadone.
Overly restrictive law or regulation: In these guidelines, the term “overly restrictive law or regulation” 
refers to drug regulatory provisions that either:
a) do not materially contribute to the prevention of misuse of the controlled medicines but do create an 
impediment to their availability and accessibility; or
b) have the potential to prevent the misuse of controlled medicines but disproportionately impede their 
availability and accessibility.
Whether a drug regulatory provision disproportionately impedes availability and accessibility of controlled 
medicines must be determined in each individual case and will depend on context, the extent of its 
contribution to preventing the misuse of the medicines, the extent to which it impedes the availability and 
accessibility of controlled medicines, and the availability of other control measures that could provide a 
similar prevention but interfere less with the availability and accessibility of the medicine.
Party or State Party to a treaty is a country that has ratified or acceded to that particular treaty, and is 
therefore legally bound by the provisions in the instrument (3). 
Preamble is an introductory statement (e.g. to a convention) (10).
Psychotropic substances is a legal term that refers to all those substances listed in the Convention on 
Psychotropic Substances.
Rational (medical) use, for the purposes of these guidelines, is defined as the appropriate use of a medicine 
by both health professionals and consumers in their respective roles. Rational medical use aims at meeting 
the clinical needs of the individual patient by prescribing, dispensing, and administering effective medicines 
for the medical condition of the patient, at the adequate dose, within the required time schedule and for the 
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required amount of time to treat or cure the patient’s medical condition; it should also enable the patient to 
adhere to such treatment. 
Regulation refers to a set of rules on a specific topic with binding legal force at the national, state or local 
level and enacted by an administrative body to which the authority to issue such rules has been delegated by 
the national, state or local legislative body.
Single Convention refers in this publication to the Single Convention on Narcotic Drugs, 1961, as amended 
by the 1972 Protocol Amending the Single Convention on Narcotic Drugs, 1961 (11).
Tolerance refers to a reduction in the sensitivity to a pharmacological agent following repeated 
administration, in which increased doses are required to produce the same magnitude of effect.
Withdrawal syndrome is the occurrence of a complex (syndrome) of uncomfortable symptoms or 
physiological changes caused by an abrupt discontinuation or a dosage decrease after repeated 
administration of a pharmacological agent. Withdrawal syndrome can also be caused by the administration 
of an antagonist.
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introduction to tHE 
GuidElinEs
Purpose, target and scope
The purpose of these guidelines is to provide authoritative guidance on policies and legislation with regards 
to availability, accessibility, affordability and control of medicines made from substances that are controlled 
under the international drug control conventions (11-13).b In this document, these medicines will be referred 
to as “controlled medicines”. 
The availability, accessibility and affordability of controlled medicines are important issues for all countries, but 
problematic for most of them. The World Health Organization (WHO) encourages governments, civil society 
and other interested individuals to strive for the maximum public health outcome of policies related to these 
medicines. WHO considers the public health outcome to be at its maximum (or “balanced”) when the optimum 
is reached between maximizing access for rational medical use and minimizing hazardous or harmful use.
It is hoped that these guidelines, by identifying and overcoming the regulatory and policy barriers to the 
rational use of controlled medicines, will enable governments to achieve better treatment of those patients 
that require them.
The guidelines’ target audience (those groups and individuals whom it is envisaged will be encouraged to 
utilize this document) is:
•	 policy-makers, regulators (in government, administrative departments, national competent 
authorities) and politicians; 
•	 academia and civil society; 
•	 healthcare professionals and their organizations;
•	 individuals (including patients and their families) and organizations whose area of work or interest is 
drug control or public health.
The scope of these guidelines is “all controlled medicines”. These are medicines made from substances controlled 
internationally under the Single Convention on Narcotic Drugs (further called “Single Convention”) and 
under the Convention on Psychotropic Substances. It also includes medicines made from precursors regulated 
under the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. 
Furthermore, they could also be other substances controlled under national drug laws and regulations. 
The guidelines pay special attention to those medicines that are also listed on the WHO Model List of 
Essential Medicines and on the WHO Model List of Essential Medicines for Children,c because these medicines 
are essential for health and health care. In addition, governments should ensure balance in policies and 
legislation with regard to other controlled medicines that are not listed as “essential medicines”. 
b Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol; Convention on Psychotropic Substances, 1971; 
United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988. 
c See Annex 1.
11Ensuring Balance in National Policies on Controlled Substances 
Background
Controlled medicines play an important role in several medical areas. Opioids are used to treat pain (opioid 
analgesia), and to treat opioid dependence (long-acting opioid agonist therapy). Other controlled medicines are 
essential in emergency obstetrics (ergometrine, ephedrine) or used as anxiolytics and hypnotics (benzodiazepines) 
or as anti-epileptics (phenobarbital and benzodiazepines).
There are a number of issues related to balanced policies and legislation that are covered by other documents. 
For example, guidance for actual treatment is covered by a number of WHO treatment guidelines that have 
been or will be developed with involvement of a group of international experts through a transparent evidence-
based process that aims to ensure their universal applicability. There are WHO treatment guidelines on opioid 
dependence, cancer pain (including cancer pain in children), emergency obstetrics and HIV/AIDS. Treatment 
guidelines relevant to this document are listed in Annex 2.
There are also a number of documents addressing practical aspects for implementing the recommendations 
from this guidelines document, such as the UNODC publication A ‘step-by-step’ algorithm for the procurement 
of controlled substances for substitution treatment, (practical information on importation of opioids) (14). 
Furthermore, Guidelines for the international provision of controlled medicines for emergency medical care 
may be applied to disaster relief settings (15). Currently, WHO and INCB are jointly developing guidelines for 
estimating requirements for controlled substances.
The central principle of “balance”
The central principle of “balance” represents a dual obligation of governments to establish a system of control 
that ensures the adequate availability of controlled substances for medical and scientific purposes, while 
simultaneously preventing abuse, diversion and trafficking. Many controlled medicines are essential medicines 
and are absolutely necessary for the relief of pain, treatment of illness and the prevention of premature death. 
To ensure the rational use of these medicines, governments should both enable and empower healthcare 
professionals to prescribe, dispense and administer them according to the individual medical needs of 
patients, ensuring that a sufficient supply is available to meet those needs. While misuse of controlled 
substances poses a risk to society, the system of control is not intended to be a barrier to their availability for 
medical and scientific purposes, nor interfere in their legitimate medical use for patient care (16).
A dual obligation, a quadruple imperative
Countries have a dual obligation with regard to these medicines based on a quadruple imperative, which is based 
on legal, political, public health and moral grounds. They must ensure that these substances are available for 
medical purposes and they must protect their populations against abuse and dependence. Indeed, here lies the 
challenge for both public-health and drug-control authorities. WHO promotes policies that simultaneously strive 
for minimizing substance abuse and maximizing access for rational medical use. The combination that leads 
to the maximum public health outcome is the optimum between these two elements, and a policy leading to 
this optimum can be called a “balanced policy” (See box above, The central principle of “balance”). WHO’s work 
towards balanced policies is supported by the INCB and the Commission on Narcotic Drugs (CND) in its Resolution 
53/4 (in paragraph 10 and also in paragraphs 4, 6 and 9) (16, 17).
Moreover, in 2008, the United Nations’ Special Rapporteur on the prevention of torture and cruel, inhuman, or 
degrading treatment or punishment, and the Special Rapporteur on the right of everyone to the enjoyment of 
the highest attainable standard of physical and mental health, jointly wrote a letter to the CND on human rights 
aspects of drug control, in which they requested that “national drug control laws recognize the indispensible 
nature of narcotic and psychotropic drugs for the relief of pain and suffering, and guarantee adequate availability 




The obligation to make controlled medicines available for medical purposes finds its legal basis in the international 
drug control conventions, which state that “the medical use of narcotic drugs continues to be indispensable for 
the relief of pain and suffering and that adequate provision must be made to ensure the availability of narcotic 
drugs for such purposes” (11).d Human rights principles supporting the duty to ensure adequate availability of 
controlled medicines for medicinal purposes are also contained in international legal instruments expressing the 
international right to health. A key instrument in this regard is the WHO Constitution, the first international legal 
instrument expressing the right to health. In the WHO Constitution, the right to health is broadly formulated as 
follows: “The States Parties to this Constitution declare, in conformity with the Charter of the United Nations, 
that the following principles are basic to the happiness, harmonious relations and security of all peoples: Health 
is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity. 
The enjoyment of the highest attainable standard of health is one of the fundamental rights of every human 
being without distinction of race, religion, political belief, economic or social condition.” (19).
Almost all countries worldwide are party to the international drug control conventions and have thus legally 
committed their governments to making controlled substances available for medical purposes. In addition, most 
countries are party to the WHO Constitution and/or the International Covenant on Economic, Social and Cultural 
Rights (20), both of which recognize the right to health. For specific controlled medicines, such as those used 
in obstetric emergencies, other human rights instruments may be applicable, including the right to life and 
provisions specifically related to the rights of women to health (21, 22).
Political imperative
In September 2000, the United Nations adopted the United Nations Millennium Declaration (23) urging their 
nations to reduce extreme poverty and setting out a series of targets with a recommended completion date of 
2015. These have become known as the Millennium Development Goals. The eight Millennium Development 
Goals (MDGs) form a blueprint that has been agreed upon by all of the world’s countries and all leading 
development institutions. 
Several MDGs affect essential medicines either directly or indirectly, including controlled medicines that are also 
listed as essential medicines. In particular, MDGs include: 
•	 “To encourage the pharmaceutical industry to make essential drugs more widely available and affordable 
for all who need them in developing countries” (MDG 8e);
•	 “...To have reduced maternal mortality by three quarters, and under-five child mortality by two thirds, of 
their current rates.” (MDG 5a);
•	 “...To have, by then, halted, and begun to reverse, the spread of HIV/AIDS, the scourge of malaria and 
other major diseases that afflict humanity.” (MDG 6a).
In the MDGs, countries also agreed to “spare no effort to ... strengthen the rule of law, as well as respect for 
all internationally recognized human rights” and “[t]o strive for the full protection and promotion in all our 
countries of civil, political, economic, social and cultural rights for all.” 
Public health imperative
Drug control should not be approached as an objective in itself, but as a tool to optimize public health.
One focus should be the prevention of abuse and dependence; the other to avoid collateral harm. The 
outcomes should be judged both by the harms from abuse it prevents and the harm it causes through, for 
example, lack of access. 
d This wording is from the Single Convention on Narcotic Drugs; the Convention on Psychotropic Substances contains similar 
wording for psychotropic substances.
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Untreated pain may cause losses to society in the form of incapacity to work, caregivers becoming unproductive 
in society due to their caring role, and pain patients needing further attention if they do not receive adequate 
pain management. Treatment of dependence syndrome may re-socialize people who previously were incapable of 
work, and may serve to reduce petty crime and the risk of harmful behaviour by the individual; it may also reduce 
the transmission of infectious disease through unsafe injection. Programmes that provide long-acting opioid 
agonist treatment (or “substitution therapy”)e are cost-effective for a country (24).
Treatment of neurological and psychiatric disorders, including epilepsy, will be more effective if the medicines 
needed for treatment are readily accessible. For emergency obstetric care, reducing the rate of maternal mortality 
is an important target which cannot be achieved without making the appropriate medicines available.
Moral imperative
Aside from a legal and a political obligation and from public health considerations, a moral imperative also exists 
to prevent suffering by making controlled medicines available and accessible; this is particularly true as suffering 
can be prevented at a relatively low cost and without too much effort.
Without any efforts for change, the current situation will continue, with every year tens of millions of people 
suffering from disease, moderate to severe pain or ultimately death (25). These include:
•	 1 million end-stage HIV/AIDS patients;
•	 5.5 million terminal cancer patients;
•	 0.8 million patients suffering injuries caused by accidents and violence;
•	 patients with chronic illnesses; 
•	 patients recovering from surgery; 
•	 women in labour (110 million births each year);
•	 paediatric patients;
•	 130 000 preventable new HIV infections and an unknown number of other blood-borne infections;
•	 75 000 women who die during childbirth. 
The consequences of a lack of availability of controlled medicines are severe and the numbers of patients afflicted 
are at least the same in magnitude as those afflicted by conditions that are recognized as major contributors to 
the world’s burden of disease; in particular HIV, malaria and tuberculosis.f
Indispensability of controlled medicines in contemporary medical practice
Analgesia
Pain is prevalent in almost all medical specialties, including in general practice, palliative care, oncology, internal 
medicine, haematology and surgery. Patients who are affected include people who have cancer, HIV, sickle-cell 
disease, or those who have had surgery or accidents.
Cancer patients may need pain relief at every stage of the disease. More than two thirds of patients with 
advanced cancer and about half of all patients with advanced HIV/AIDS will experience moderate to severe pain 
(25, 29, 30). In obstetrics, women may need pain relief during labour, surgery and post-surgery. 
e The wording “substitution therapy” is misleading because it is not just replacing illicit drugs by officially approved drugs; there 
is evidence now that hormone levels are normalized and because of the slow onset of the medicines used, there is no immediate 
awarding sensation or “kick”. Therefore, the terminology “long-acting opioid agonist therapy” or “opioid agonist therapy” is preferred.
f HIV: incidence: 2.7 million/yr, prevalence: 33.4 million/yr, mortality: 2.0 million/yr (2008) (26)
 Malaria: incidence: 243 million/yr, mortality: 863 000/yr (2008) (27)
 Tuberculosis: incidence: 9.4 million/yr, prevalence: 11.1 million/yr, mortality: 1.3 million (2008) (28)
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For all of these patients, pain relief should be part of their overall treatment. Oral opioids are key components 
for the treatment of moderate to severe pain and several are regarded as essential medicines (25, 31, 32). 
Paracetamol (acetaminophen), acetylsalicylic acid, non-steroidal anti-inflammatory medicines (NSAIMs) when 
used alone and weak acting opioids (tramadol, codeine) are usually not effective in the case of moderate to 
severe pain. NSAIMs can have serious side-effects and should be used with caution on a chronic basis (33, 34). 
Despite a century of pharmaceutical chemistry, suitable alternatives to strong opioids for treatment of moderate 
to severe pain have yet to be found.
Unrelieved pain can impair all aspects of a person’s life, impacting on emotional, physical and social functioning; 
unrelieved severe pain can even result in a wish for death to occur (35).
Treatment of opioid dependence syndrome and prevention of HIV
Globally, there are an estimated 16 million people who inject illicit drugs (36). The number of people who are 
dependent on opioids who do not inject is much higher. In 2008, UNODC estimated that globally, between 12.8 
and 21.9 million people illicitly used opioids over the previous 12 months, with the prevalence ranging between 
0.3% and 0.5% of the world’s population aged 15 - 64 (37). Of the new HIV infections in Eastern Europe and 
Central Asia in 2005, 62% were due to injection drug use (38). 
There is strong evidence for the efficacy of treatment of opioid dependence with long-acting opioid agonists 
such as oral methadone and buprenorphine which effectively reduce and prevent injecting drug use and thus 
contribute to containing hepatitis B and C and the HIV/AIDS epidemic. Treatment with long-acting opioid 
agonists also reduces mortality from heroin overdose by 90% (39). Moreover, it allows patients with opioid 
dependence to function more fully in society. Dependence is a disorder associated with neurobiological changes 
in opioid peptides and other neuropeptides that can be stabilized with long-acting opioid therapy (40); legislation 
should therefore focus on treatment, not punishment. However, it is estimated that, worldwide, only 8% of 
injecting drug users have access to treatment for opioid dependence (41).
Other uses of essential controlled medicines
Opioids are also used in anaesthesia and, additionally, morphine is used for treating dyspnoea and anxiety 
resulting from dyspnoea. Codeine and some other weak acting opioids are used to treat coughs and diarrhoea. 
Ergometrine and ephedrine, two substances frequently diverted for the production of illicit drugs, play important 
roles in emergency obstetrics and can prevent maternal death. Each year, half a million women die during 
childbirth (42), about 120 000 of them from post-partum bleeding (43). Many of these lives could be saved if 
medicines to stop the bleeding were more widely available.
Ketamine is an essential medicine, pivotal for anaesthesia. In rural areas of developing countries in particular, 
ketamine is the only suitable and safe anaesthetic. Although not listed in the international drug treaties, 
ketamine is now under national control in approximately 50 countries worldwide. In 2006, the CND called upon 
governments “to consider controlling the use of ketamine by placing it on the list of substances controlled under 
their national legislation, where the domestic situation so requires” (44, 45). Ketamine is still under review by 
WHO’s Expert Committee on Drug Dependence (46). National control policies with regard to ketamine should be 
balanced in order to ensure surgery is available to rural populations (47).
Other medicines are important for neurology and psychiatry, for example in the treatment of epilepsy, anxiety 
and sleeplessness. In some countries, overconsumption of benzodiazepines as hypnotics and anxiolytics occurs. 
When used as hypnotics and anxiolytics, they are indicated for use during a brief period in crisis situations only, 
but are often prescribed for extended periods. On the other hand, controlled medicines for the treatment of 
epilepsy, such as phenobarbital and benzodiazepines, may scarcely be available. In Africa, 80% of the population 
affected by epilepsy has no access to essential antiepileptic medicines (48).
Finally, controlled substances are important for scientific purposes, e.g. for medical research (including clinical 
trials), for research into dependence, and for use in forensic laboratories.
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Safety of controlled medicines
It should be recognized that controlled medicines when used rationally for medical purposes are safe medicines. 
Opioid analgesics, if prescribed in accordance with established dosage regimens, are known to be safe and there 
is no need to fear accidental death or dependence. A systematic review of research papers concludes that only 
0.43% of patients with no previous history of substance abuse treated with opioid analgesics to relieve pain 
abused their medication and only 0.05% developed dependence syndrome (49).  
This may be explained by a postulated neurobiological mechanism (50).
Current availability
The total global consumption of opioids increased significantly after 1986, when WHO introduced the Analgesic 
Ladder for cancer pain relief. However, the increase occurred in a limited number of mainly industrialized 
countries that represent only a small part of the world’s population (51, 52). It is estimated that 80% of the 
world’s population does not have access to morphine for pain relief (53).
MorPhine: distribution of consuMPtion, 2009
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Any statistics contain an inherent inaccuracy (usually from underreporting) and this will be equally true for 
the statistics on controlled substances. However, the statistics on narcotic drugs and psychotropic substances 
published by the INCB (53) can be considered as reliable, because the administrative systems provided for by the 
Single Convention and the 1971 Convention obligate governments to report statistical data to the INCB, which 
then investigates any inconsistencies.
For the treatment of opioid dependence syndrome, despite the fact that injecting drug use has been reported 
from almost every country in the world, only 70 countries (out of 193) have services where long-acting opioid 
agonist therapy is operational, and it is estimated that worldwide only 8% of injecting drug users receive this 
therapy (compared to 61% in Western Europe, where it is a standard treatment option) (41). 
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Impediments to availability, accessibility and affordability
It is almost a century since the first international drug control convention came into force (54), and the 
drug control conventions that established the dual obligation of ensuring adequate availability of controlled 
medications and of preventing their misuse have existed for almost 50 years. Yet the obligation to prevent abuse 
of controlled substances has received far more attention than the obligation to ensure their adequate availability 
for medical and scientific purposes, and this has resulted in countries adopting laws and regulations that 
consistently and severely impede accessibility of controlled medicines. 
The INCB and WHO have highlighted overly restrictive laws and regulations that impede the adequate availability 
and medical use of opioids (31, 32, 51, 55 - 58). As far back as 1989 (55), the INCB drew attention to some 
governments’ overreaction to the drug abuse problem when “the reaction of some legislators and administrators 
to the fear of drug abuse developing or spreading has led to the enactment of laws and regulations that may, in 
some cases, unduly impede the availability of opiates”. INCB also stated that “legislators sometimes enact laws 
which not only deal with the illicit traffic itself, but also impinge on some aspects of licit trade and use, without 
first having adequately assessed the impact of the new laws on such licit activity. Heightened concern with the 
possibility of abuse may also lead to the adoption of overly restrictive regulations which have the practical effect 
of reducing availability for licit purposes”.
In each guideline of this document, the type of measures that contribute or do not contribute to the prevention 
of abuse and dependence and the type of measures that are an impediment to availability and accessibility for 
rational medical use are explained. Many practical examples of barriers at various levels are provided, including:
•	 legislation and policy;
•	 knowledge and societal attitude;
•	 economic aspects, including affordability.
In order to improve access, governments should work continuously on all of these aspects in order to make 
controlled medicines available, accessible and affordable.
Why and how to work with this document?
The imperative for evaluation of national drug control policies
For a quarter of a century, attention has been drawn to the fact that the level of consumption of controlled 
medicines worldwide does not match the needs for health care. In some countries the consumption level has 
improved over this period, but in most countries there has been little significant change. 
In 2010, the INCB stated that “discrepancies in the consumption levels of opioid analgesics in different countries 
continue to be very significant. Factors such as knowledge limitations and administrative barriers stricter than 
the control measures required under the 1961 Convention affect the availability of opioid analgesics”. The 
INCB requested “the Governments concerned to identify the impediments in their countries to access to and 
adequate use” (52). Also, as INCB had done previously, CND and WHO have called on governments to evaluate 
their healthcare systems and laws and regulations, and to identify and remove impediments to the availability of 
controlled substances for medical needs (16, 31, 32, 51, 55 - 57). 
Using the guidelines
The guidelines in the next chapter may be used by governments, health professionals and others. The guidelines 
can be used as:
•	 a policy and legislation evaluation tool;
•	 a basis for formulating new policies and legislation or improving existing policies and legislation;
•	 an educational tool to inform interested parties about the relationship between national drug control 
policy and legislation and the availability and accessibility of controlled medicines.
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Strategies to make controlled medicines readily available and accessible include: 
•	 review of legislation and its subsequent amendment;
•	 planning for improved availability, through 
 ‣ developing good annual estimates and statistics (and submitting them to the INCB);
 ‣ integrating access to controlled medicines into health and disease control policies;
 ‣ establishing adequate services where patients can obtain rational treatment without interruption;
 ‣ education of healthcare professionals and the general public.
The need to evaluate policy is clear, but the process may not be. Several steps are recommended to governments.
•	 Designate a person or committee (for example, the national competent authority or health professionals) 
to study the guidelines. Governments may wish to organize a special meeting or workshop of regulators 
and healthcare practitioners to discuss and complete the Country Assessment Checklist (as some of the 
questions are legal ones and others are policy ones, in the case of a committee, it may be necessary to 
establish both a legal and a policy sub-committee);
•	 Obtain additional information from the key resource materials (see the CD-ROM);
•	 Obtain up-to-date copies of the national drug control policies and legislation;
•	 Use the Country Assessment Checklist to assess the legislation and the policies;
•	 Establish dialogue between policy-makers, academia and civil society to make the necessary changes.
For educational purposes, the guidelines can be distributed to the relevant governmental and nongovernmental 
organizations, especially to those individuals and groups who are involved in drug control and improvement of 
pain relief, cancer services, palliative care, treatment of dependence, medical education, etc.
Countries who wish to work on formulating new policy or improving existing policies and legislation may want to 
work with WHO’s Access to Controlled Medications Programme (ACMP). The ACMP was jointly developed by INCB 
and WHO, and is operated by WHO. In its 2009 Report, the INCB recommended that “the Access to Controlled 
Medications Programme … will provide effective assistance to Governments in promoting rational use of opioid 
analgesics. The Board calls upon Governments to support and cooperate with WHO in the implementation of the 
Access to Controlled Medications Programme” (52). Furthermore, the WHO Collaborating Centre for Pain Policy 
and Palliative Care (University of Wisconsin, Madison WI, United States) can assist in various ways and makes 
relevant resources available on its website.g
Using the Country Assessment Checklist
A Country Assessment Checklist is provided below that enables users to check the extent to which the guidelines 
in this document are adhered to in a given country. It may be used as a tool for the analysis of national policies 
and legislation.
The numbering refers to the guidelines and indicates whether a question is on legal or policy issues. This may 
enhance assessment by teams who want to split their work over policy and legal sub-teams.
For most questions, the answer that is most favourable for ensuring good access and availability to controlled 
medicines is represented in bold. Thus, for any question where the answer is not presented in bold, there is an 
opportunity to work on improvement. By working systematically on these issues, a country can gradually improve 
access and availability of controlled medicines. A systematic approach also necessitates subsequent completion of 
the Country Assessment Checklist at a later date.
g  www.painpolicy.wisc.edu (accessed 31 December 2010).
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GuidElinEs for EnsurinG 
balancE in national 
PoliciEs on controllEd 
substancEs 
content of drug control legislation and policy
 GuIdelIne 1 
National drug control policies should recognize that controlled medicines are absolutely 
necessary for medical and scientific purposes. 
It can be considered as a condition sine-qua-non for enabling and facilitating availability and 
accessibility of controlled medicines, that national policies are explicit about their objectives. 
National policies should recognize the necessity of controlled medicines and ensure they put in place 
policy statements to ensure implementation of the policies. Such statements would include those on 
improving access to all in need. Moreover, countries may want to establish this in their law, either 
as an objective or an obligation for the government. This would mirror the imperative stated in the 
international drug control treaties to make narcotic drugs and psychotropic substances available for 
medical use. 
Relevant international lawh and principles
Single Convention on Narcotic Drugs, Preamble, paragraph 2 (11): “Recognizing that the medical use of 
narcotic drugs continues to be indispensable for the relief of pain and suffering and that adequate provision 
must be made to ensure the availability of narcotic drugs for such purposes.”
Convention on Psychotropic Substances (59) Preamble paragraph 5: “Recognizing that the use of psychotropic 
substances for medical and scientific purposes is indispensable and that their availability for such purposes 
should not be unduly restricted.”
 GuIdelIne 2 
Governments should comply with their international legal obligations to ensure adequate 
availability and accessibility of controlled medicines for all medical and scientific purposes 
through national legislation and drug control policies. 
Governments have an international legal responsibility to comply with all the treaties to which they 
are a party. This responsibility does not just fall on one agency or sector but on the government as 
a whole. As such, drug control authorities need to comply not only with the drug control treaties 
but also with obligations that flow from other treaties, including international human rights 
instruments. Conversely, other government agencies have to ensure that legislation/regulations 
under their responsibility comply with international drug control conventions.
The international drug control conventions provide the basic framework for national drug control 
legislation. In its 2009 annual report, the INCB once again declared that: “One of the fundamental 
objectives of the international drug control treaties is to ensure the availability of narcotic drugs 
and psychotropic substances for medical and scientific purposes and to promote access to and 
rational use of narcotic drugs and psychotropic substances” (52). 
International human rights treaties and other instruments provide a further source of guidance 
related to the availability and accessibility of controlled medicines. The right to health, which is 
recognized in some form by almost all countries, is secured in a number of treaties and other legal 
instruments (60). For example, the Constitution of the World Health Organization provides the first 
legal expression of the international right to health. In addition, Article 12 of the International 
h For more details: see the original texts of the conventions. 
20
21Ensuring Balance in National Policies on Controlled Substances 
Convenant on Economic, Social and Cultural Rights (ICESCR) (61) further articulates the right to 
health. i The Committee on Economic, Social and Cultural Rights, established by ECOSOC, prepared 
General Comment 14 to further elaborate on the content of the right to health. Although 
technically non-binding as a matter of international law, the General Comment was designed by the 
Committee to serve as an authoritative interpretation of Article 12.
The international drug conventions and the principle of the right to health complement each 
other; the first consideration of the Preamble of the Single Convention reads: “The Parties [to this 
Convention], Concerned with the health and welfare of mankind …”. 
Advocates argue that international human rights principles require that governments must provide 
essential medicines - which include controlled medicines - as part of their minimum core obligations 
under the right to health. In addition, other advocates have linked access to controlled medicines 
to the human rights obligation of governments to take measures to protect people under their 
jurisdiction from inhuman and degrading treatment (18).
In 2005, the UN’s Economic and Social Council (ECOSOC) and the World Health Assembly urged 
countries to ensure the medical availability of opioid analgesics according to international treaties 
(62, 63).
In a 2009 report to the Human Rights Council (64), the Special Rapporteur on torture and other 
cruel, inhuman or degrading treatment or punishment declared that he “wishes to recall that, from a 
human rights perspective, drug dependence should be treated like any other health-care condition” 
(paragraph 71), and that “Given that lack of access to pain treatment and opioid analgesics for 
patients in need might amount to cruel, inhuman and degrading treatment, all measures should be 
taken to ensure full access and to overcome current regulatory, educational and attitudinal obstacles 
to ensure full access to palliative care” (paragraph 74(e)).
Relevant international law and principles
Single Convention, Article 4: “the parties shall take such legislative and administrative measures as may be necessary ... to 
limit exclusively to medical and scientific purposes the production, manufacture ... distribution ... use and possession of 
drugs”.
Convention on Psychotropic Substances (59), Article 5, paragraph 2: “Each Party shall ... limit ... as it considers appropriate 
the manufacture … distribution ... use and possession of substances in Schedules II, III and IV to medical and scientific 
purposes”.j
Single Convention, Article 38, paragraph 1: Countries have an obligation to provide both prevention and treatment of 
substance dependence. The Article declares: “The Parties shall … take all practicable measures for the prevention of abuse 
of drugs and for the … treatment … of the persons involved”. The Convention on Psychotropic Substances, Article 20, 
paragraph 1, contains almost identical wording.
International Covenant on Economic, Social and Cultural Rights (ICESCR), Article 12 (61): “1. The States Parties to the 
present Covenant recognize the right of everyone to the enjoyment of the highest attainable standard of physical and 
mental health. 2. The steps to be taken by the States Parties ... to achieve the full realization of this right shall include … 
the ... treatment and control of ... diseases [and] the creation of conditions which would assure to all medical service and 
medical attention in the event of sickness”.
General Comment 14 to Article 12, ICESCR includes (60):
	‣ The right of … access to ... appropriate treatment of prevalent diseases, illnesses, injuries and disabilities, preferably at 
community level; the provision of essential drugs; and appropriate mental health treatment and care (paragraph 17);
	‣ The importance of an integrated approach ... based on … attention and care for chronically and terminally ill persons, 
i 193 countries are Member States to the World Health Organization; 160 countries are parties to the ICESCR (http://treaties.
un.org/Pages/ViewDetails.aspx?src=TREATY&mtdsg_no=IV-3&chapter=4&lang=en; accessed 3 January 2011).
j Stricter limitation is required for substances in Schedule I of the Convention on Psychotropic Substances, as is explained in Article 
7. These substances are of limited medical use, but if they are needed, even their use can be allowed.
22
sparing them avoidable pain and enabling them to die with dignity (paragraph 25);
	‣ The right to healthy natural and workplace environments … [and] the obligation of States parties … to provide 
... information campaigns ... with respect to HIV/AIDS [and] the abuse of ... drugs and other harmful substances 
(paragraphs 15 and 36); 
	‣ The core obligation ... to provide essential drugs, as from time to time defined under the WHO Action Programme on 
Essential [Medicines] (paragraph 43d);
	‣ The core obligation ... to ensure equitable distribution of all health facilities, goods and services (paragraph 43e);
	‣ The core obligation to ensure reproductive, maternal … care (paragraph 44a);
	‣ The core obligation ... to provide appropriate training for health personnel, including education on health and human 
rights (paragraph 44e).
Constitution of the World Health Organization, Preamble: “The States Parties to this Constitution declare, in conformity 
with the Charter of the United Nations, that the following principles are basic to the happiness, harmonious relations and 
security of all peoples: Health is a state of complete physical, mental and social well-being and not merely the absence of 
disease or infirmity. The enjoyment of the highest attainable standard of health is one of the fundamental rights of every 
human being without distinction of race, religion, political belief, economic or social condition” (19).
Other human rights treaties relevant to the right to health exist as well, such as the Convention on the Rights of the 
Child (3) and others of regional importance, such as the African Charter on the Rights and Welfare of the Child (65), 
the African Charter on Human and Peoples’ Rights (66), the [European] Convention for the Protection of Human Rights 
and Fundamental Freedoms (67), the European Social Charter of 1961 (68), and the Additional Protocol to the American 
Convention on Human Rights in the Area of Economic, Social and Cultural Rights (69).
Authorities and their role in the system
 GuIdelIne 3 
Governments should designate a National Authority for ensuring adequate availability and 
accessibility of controlled medicines in health care. 
The INCB recommends that “Governments should determine whether their national narcotic laws 
contain elements ... that take into account...the fact...that adequate provision must be made to 
ensure the availability of narcotic drugs for such purposes...[and] to ensure that administrative 
responsibility has been established and that personnel are available for the implementation of those 
laws.” (51). Such an authority could be part of the National Competent Authority or a separate 
office, whatsoever is the most appropriate in the national situation.
 GuIdelIne 4 
Governments should ensure that all authorities involved in developing and implementing 
policies on controlled substances cooperate and meet as necessary for the promotion 
of their availability and accessibility for medical and scientific purposes as well as the 
prevention of abuse, dependence syndrome and diversion.
To formulate and implement coherent drug control policies, countries need to ensure that 
relevant government agencies work in cooperation with each other and that their policies and 
regulations are closely aligned. In order to be effective, such meetings should be held as necessary, 
depending on national circumstances. Relevant agencies include drug control legislators, healthcare 
authorities, customs officials, police, and members of the judiciary. Their cooperation will allow for 
all participants to be more effective, and ensure synergy between their policies. Agencies will also 
develop a better understanding of each other’s concerns, constraints and challenges, resulting in 
opportunities to collaborate jointly to achieve controlled medicines’ availability for rational medical 
use and to decide on and implement the necessary measures for balancing national control policies. 
The National Authority referred to in Guideline 3 should be actively involved.
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 GuIdelIne 5 
Governments should ensure that there is a forum where drug control authorities and public 
health authorities cooperate and meet as necessary with health professional organizations 
and other stakeholders for the promotion of the availability and accessibility of controlled 
medicines for medical and scientific purposes, as well as the prevention of abuse, 
dependence syndrome and diversion.
Communication between relevant national authorities (including the National Authority to be 
designated under Guideline 3), health workers and other stakeholders is essential in order to ensure 
that each understands the other’s aims and mandate. In order to be effective, such meetings should 
be held as necessary, depending on national circumstances. This will enable health workers and 
their associations to provide information on needs for controlled substances and to be aware of 
the concerns of regulators. In turn, regulators will be able to learn in more detail about the effects 
of legislation and policy on medical care and the importance of controlled medicines for both 
individual patients and public health in general.
Such cooperation could take the form of a National Advisory Board of relevant stakeholders, 
including government authorities, medical boards, representatives of health professionals, patients 
and health insurances, and those parts of the administration responsible for public health care 
requiring controlled medicines, including drug control enforcement officials and legislators. If 
appropriate, this could also include police, customs officials and members of the judiciary. 
The overall mandate of the National Advisory Board would be to advise on how to achieve the 
balance between availability of controlled medicines for medical use and prevention of substance 
abuse and dependence. The work of the National Advisory Board, depending on composition and 
mandate, could comprise the following aspects:
 ‣ to assist the needs assessment for controlled medicines and to report on the degree of access;
 ‣ to advise on the promotion of rational use of controlled medicines, implementation of best 
practices, development of national treatment guidelines and implementation of international 
treatment guidelines.
 GuIdelIne 6 
All government agencies, depending on their roles and obligations, should ensure that in 
the fulfilment of their duties, they do not impede health policies and access to legitimate 
treatment with controlled medicines. Health authorities should provide relevant information 
on treatment principles to drug law enforcement and other relevant agencies.
The conventions require prohibition of drug possession if not “under legal authority”. As health workers 
“while performing therapeutic functions” do not need a license or a prescription, the professional 
possession of controlled medicines should be considered “under legal authority” and is therefore 
not prohibited. Similarly, patients who obtained controlled medicines on medical prescription from 
authorized dispensing pharmacies and health facilities possess such medicines “under legal authority”. 
The conventions place an obligation on governments to provide education to people who work 
on drug control. All agencies involved with drug control (for example, customs officials and the 
police), should therefore have sufficient knowledge of the government’s health policy with regard 
to treatment with controlled medicines. Their knowledge should be sufficient to understand when 
it is lawful for patients and health professionals to be in possession of medicines and that they 
should not exert excessive control measures. This principle also applies to treatment of opioid 
dependence; law enforcement should not prevent such patients from undergoing treatment. 
Provision of information and education about treatment and use of controlled medicines should not 
be considered as promotion of illegal drugs and not lead to prosecution.
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Relevant international law and principles
Single Convention, Article 38, paragraph 3, requires that governments “shall assist persons whose work so requires to gain 
an understanding of the problems of abuse of drugs and of its prevention”. The Convention on Psychotropic Substances, 
Article 20, contains almost identical wording.
Single Convention, Article 33: prohibits “the possession of drugs except under legal authority”. 
Article 30, paragraph 1.a: in case of distribution, a license is required, but (Article 30, paragraph 1.c) this “need not apply to 
persons duly authorized to perform and while performing therapeutic or scientific functions”. Similarly, the supply or the 
dispensing of medicines to individuals requires a prescription (Article 30, paragraph 2.b.i) and therefore any patient who 
obtained his medicines with a prescription can be considered to possess his medicines under legal authority as mentioned 
in Article 33. Article 30, paragraph 2.b.i also declares that “this requirement need not apply to such drugs as individuals 
may lawfully obtain, use, dispense or administer in connexion with their duly authorized therapeutic functions”. 
Convention on Psychotropic Substances, Article 8, paragraph 1 requires licensing of distribution of substances listed in 
Schedules II, III and IV, but “licensing or other similar control measures need not apply to persons duly authorized to 
perform and while performing therapeutic or scientific functions” (Article 8, paragraph 3). Possession is also allowed “under 
legal authority”, e.g. healthcare workers using the medicines professionally, or patients to whom medicines were prescribed 
(Article 5, paragraph 3). 
Convention on Psychotropic Substances, Article 10, paragraph 2: “Each Party shall, with due regard to its constitutional 
provisions, prohibit the advertisement of such substances to the general public”. (Note that this is limited to advertising). 
Policy planning for availability and accessibility
 GuIdelIne 7 
Governments should include the availability and accessibility of controlled medicines for 
all relevant medical uses in their national pharmaceutical policy plans. They should also 
include the relevant controlled medicines and relevant services in specific national disease 
control programmes and other public health policies. 
Planning for availability through the formulation of policy plans is essential for defining and 
realizing the health policy objectives of a country. It is also essential for the realization of a country’s 
international obligations with respect to the international drug conventions and human rights 
conventions.
The objective to make controlled medicines available and accessible for all medical and scientific 
purposes in the national medicines policy plan should be stipulated at the outset. Policies should also 
address availability of controlled medicines for scientific purposes, as research with these substances 
may be necessary for such use.
Only after establishing this general policy should specific policy plans be developed for individual 
diseases. As a minimum, countries should ensure that availability and accessibility of controlled 
medicines is addressed for the following disease-specific policies:
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DISEASE PROGRAMME ITEMS TO INCLUDE IN THE PROGRAMME
Cancer control • access to and availability of strong opioid analgesics (70)
• integrated hospice and palliative care services (71)
HIV/AIDS • access to and availability of strong opioid analgesics (70)
• integrated hospice and palliative care services (71)
•  prevention of HIV transmission through availability and 
accessibility of opioid agonist therapy (72, 73)
Mental health (substance 
abuse and dependence 
syndrome)
• prevention of substance abuse and dependence syndrome (74)
•  treatment of dependence syndrome through availability and 
accessibility of opioid agonist therapy (24)
Mental health (other 
psychiatric and neurological 
disorders)
•  availability and accessibility of anxiolytics, hypnotics and 
antiepileptics
Maternal health •  availability and accessibility of oxytocin (not-controlled)  
and/or ergometrine and of ephedrine for emergency obstetric  
care (75 - 77)
However, all governments should ensure that patients have pain relief in accordance with 
national and international treatment guidelines, and access to controlled medicines should not be 
restricted to the above groups only. When developing and implementing policies on availability 
and accessibility of controlled medicines, it is important to avoid introducing rights for certain 
patient groups that could be construed as withholding this right to other patient groups. Similarly, 
there should not be a geographical restriction of availability within the country. The continuum of 
care from the family and community level to the highest levels of specialization, such as university 
hospitals, should also be ensured. 
It is essential that government policies ensure that patients are able to continue their treatment 
with controlled medicines when they are hospitalized in health facilities that normally do not use 
such medicines. 
Governments should identify and establish a List of Essential Medicines, modeled after the WHO 
Model List of Essential Medicines and the WHO Model List of Essential Medicines for Children, which 
include controlled medicines needed to cover the most pressing needs of the population.
Moreover, general policies should be developed that address the rational use of controlled 
medicines. Such policies could include an information campaign, or campaigns to address myths 
and stereotypes about opioids. Patients and their families should be informed about the treatment 
of pain and treatment of dependence. Involving the patient and the patient’s family will lead to a 
better understanding and “ownership” of the issue.
Relevant international law and principles
General Comment 14 to ICESCR: the Right to Health “must be understood as a right to the enjoyment of a variety of 
facilities, goods, services and conditions necessary for the realization of the highest attainable standard of health” 
(paragraph 9). “While the Covenant provides for progressive realization and acknowledges the constraints due to the 
limits of available resources, it also imposes on States parties various obligations which are of immediate effect. States 
parties have immediate obligations in relation to the right to health, such as ... the obligation to take steps towards the 
full realization of article 12. Such steps must be deliberate, concrete and targeted towards the full realization of the right 
to health” (paragraph 30). “[P]rogressive realization means that States parties have a specific and continuing obligation to 
move as expeditiously and effectively as possible towards the full realization of article 12” (paragraph 31).
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 GuIdelIne 8 
Governments should ensure that all population groups without discrimination equally 
benefit from their policies on the availability and accessibility of controlled medicines for 
rational medical use and the prevention of diversion, abuse, and dependence syndrome.
Non-discrimination is a fundamental principle that runs throughout the entire body of international 
human rights law. 
When developing policies and establishing treatment services, governments should not only guard 
against deliberate discrimination, but also ensure that the policies do not unintentionally lead 
to discrimination against vulnerable groups. A number of groups, including women, children, the 
elderly, people in lower income classes, ethnic minorities, prisoners, people living with HIV, sex 
workers, men who have sex with men, and injecting drug users, are particularly vulnerable and may 
require a special effort to ensure realistic access to controlled medicines. When designing policies, it 
should be ensured that such policies and resultant services allow for equal access and availability for 
these groups and are both gender sensitive and culturally appropriate.
Patients who have a history of substance abuse have as much right to be treated for their pain as 
anybody else, and regulations should not limit their access to essential medicines. It is a medical 
decision to consider the advantages and disadvantages of different treatment options. The fact 
that someone has or had opioid dependence syndrome is not a reason to withhold adequate pain 
management from that person. 
In some countries, only HIV-positive patients are allowed access, in other countries only HIV-
negative patients (78). Yet access to treatment of opioid dependence syndrome should be equal for 
both HIV-positive and HIV-negative patients. There is no medical reason to distinguish between the 
two groups and it is best practice to allow all patients access to treatment (79).
It is also important that treatment continues for people requiring controlled medicines when they are 
arrested or imprisoned, regardless of whether they are on pain treatment, treatment for dependence 
syndrome or for other diseases. Prisons should have functioning treatment programmes for opioid 
dependence. The use or threat of painful withdrawal to coerce confessions from people with opioid 
dependence may constitute torture, cruel, inhuman or degrading treatment or punishment and would 
therefore be prohibited under international human rights law (30, 74, 79 - 81).
The availability of treatment facilities in prisons also helps to diminish the illicit drug problem within 
them (79). The INCB declared in its 2007 annual report that: “Governments have a responsibility to 
reduce the availability of illicit drugs in prisons, [and] provide adequate services for drug offenders 
(whether in treatment services or in prison)” (45).
In countries where long-acting opioid agonists are available for the treatment of heroin dependence 
syndrome, pregnant women are frequently denied this option as doctors fear for the health of the 
unborn child. Evidence shows that while a child may be born with opioid withdrawal syndrome, 
it can be weaned off shortly after birth. If abstinence from heroin is not an option for a woman 
during her pregnancy, she may avoid visiting medical services, and this may result in a much more 
complicated birth and even greater threats to the child’s health (24, 82).
Relevant international law and principles
The Universal Declaration of Human Rights, Article 2: “Everyone is entitled to all the rights and freedoms set forth in this 
Declaration, without distinction of any kind, such as race, colour, sex, language, religion, political or other opinion, national 
or social origin, property, birth or other status. Furthermore, no distinction shall be made on the basis of the political, 
jurisdictional or international status of the country or territory to which a person belongs, whether it be independent, 
trust, non-self-governing or under any other limitation of sovereignty” (83).
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ICESCR, Article 2, paragraph 2: obligates countries “to guarantee that the rights enunciated in the present Covenant will be 
exercised without discrimination of any kind as to race, colour, sex, language, religion, political or other opinion, national 
or social origin, property, birth or other status”. 
General Comment 14, paragraph 34: “In particular, States are under the obligation to respect the right to health by, inter 
alia, refraining from denying or limiting equal access for all persons, including prisoners or detainees, minorities, asylum 
seekers and illegal immigrants, to preventive, curative and palliative health services”.
 GuIdelIne 9 
Governments should examine their drug control legislation and policies for the presence 
of overly restrictive provisions that affect delivery of appropriate medical care involving 
controlled medicines. They should also ensure that provisions aim at optimizing health 
outcomes and take corrective action as needed. Decisions which are ordinarily medical in 
nature should be taken by health professionals.
In many countries, national legislation includes provisions stricter than the international drug 
control conventions require. This is allowed for by the conventions, as far as it is in the opinion of 
the government “necessary or desirable for the protection of the public health or welfare”. However, 
in practice, many stricter provisions do not contribute to a better public or individual health. 
Therefore, it is important to analyze the effects of any stricter rules on the prevention of diversion, 
abuse and dependence syndrome and on the availability and accessibility of controlled medicines. 
Rules (and policies) that do not contribute to the protection of public health or welfare should 
be eliminated or changed. Rules violating any other international obligation, regardless whether 
originating from the drug conventions or any other treaty, should be guarded against.
Such an analysis should be undertaken rule by rule, and cover both legislation and official policy. If 
a rule provides a barrier for availability and accessibility, but does not contribute to the prevention 
of abuse, diversion and dependence syndrome, this rule does not contribute to the protection of 
public health or welfare, and should therefore be either eliminated or changed. In the case where 
a rule both contributes to prevention and constitutes a barrier for medical use at the same time, 
alternative ways of providing the same level of prevention without posing a barrier to rational 
medical use should be explored. This publication provides a check list that may be used for assessing 
which rules are overly restrictive and may therefore be in need of correction.
Many examples of overly restrictive laws and policies are provided in the existing literature (84 - 89). 
They may affect the healthcare worker and the way controlled medicines can be used, but they may 
also affect the patient in a negative manner. 
 ‣ The conventions do not define the length of a medical prescription or the amount of medicines 
to be prescribed by a health worker. If a prescription covers only the amount of medicines 
needed for a limited time span, or if the validity of prescriptions is limited, the patient will need 
to go frequently to the physician and the pharmacy. 
 ‣ Some countries require a system of registration and authorization for patients to render 
themselves eligible to receive a prescription for a controlled medicine. There is no requirement 
for such a system by the drug control conventions. This system may be a barrier for accessing 
treatment and delay the onset of or adherence to treatment. 
 ‣ Registration of patients treated with opioids for opioid dependence (in particular central 
registration of patients) can provide more accurate data on treatment numbers and prevent 
patients from receiving methadone or buprenorphine from more than one source. Registration 
may result in a breach of patient privacy. This may deter some patients from entering treatment 
and it can delay the commencement of treatment. This can be aggravated if registration also 
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results in refusal of a driver’s license, government employment, housing, or denial of child 
custody, for example. Such registries may severely interfere with public health policies to 
provide treatment for dependence and HIV prevention. Safe and effective treatment of opioid 
dependence can be achieved without registration. Because such registration could cause harm 
if privacy is breached, it should only be used if government agencies have effective systems for 
maintaining privacy. 
 ‣ Requirements for duplicate prescriptions and special prescription forms increases the 
administrative burden both for healthcare workers and drug control authorities. The problem is 
compounded if forms are not readily available, or if health professionals need to pay for them. 
The conventions allow for duplicate prescriptions and special prescription forms if countries 
consider them necessary or desirable. Governments should ensure that this system does not 
impede the availability and accessibility of controlled medicines.
 ‣ In many countries, retail and hospital pharmacies and dispensaries are allowed to procure, stock, 
and dispense controlled medicines by virtue of their general license; however, some countries 
require them to obtain a special license. In some cases, application procedures for such licenses 
dissuade healthcare institutions from obtaining them; for example, through overly burdensome 
bureaucratic procedures, unnecessary levels of paperwork, excessive screening of staff authorized 
to handle controlled medicines, or overspecification of special storage facilities.
 ‣ Some countries maintain severe punitive provisions for errors or problems in the prescribing and 
dispensing of controlled medicines that deter healthcare workers from legitimated prescribing and 
dispensing of these medicines. The INCB has stated: “Health professionals … should be able to … 
[provide opiates] without unnecessary fear of sanctions for unintended violations [including] … legal 
action for technical violations of the law … [that] may tend to inhibit prescribing or dispensing of 
opiates”(55). Unintentional errors that do not result in diversion of controlled medicines or serious 
health consequences should not be subject to criminal penalties.
Relevant international law and principles
Single Convention, Article 39: “Notwithstanding anything contained in this Convention, a Party shall not be, or be deemed 
to be, precluded from adopting measures of control more strict or severe than those provided by this Convention and in 
particular from requiring that preparations in Schedule III or drugs in Schedule II be subject to all or such of the measures 
of control applicable to drugs in Schedule I as in its opinion is necessary or desirable for the protection of the public health 
or welfare”.
Article 30, paragraph 2 (b ii): “The Parties shall also … [i]f the Parties deem these measures [of requiring medical 
prescriptions for the supply, or dispensation of drugs to individuals] necessary or desirable, require that prescriptions for 
drugs in Schedule I should be written on official forms to be issued in the form of counterfoil books by the competent 
governmental authorities or by authorized professional associations”.
Convention on Psychotropic Substances, Article 23: “A Party may adopt more strict or severe measures of control than 
those provided by this Convention if, in its opinion, such measures are desirable or necessary for the protection of the 
public health and welfare”. 
 
See also the obligations and principles stemming from the right to health discussed above.
 GuIdelIne 10 
Terminology in national drug control legislation and policies should be clear and unambiguous 
in order not to confuse the use of controlled medicines for medical and scientific purposes 
with misuse. 
Drug control legislation and policy have sometimes contributed to stigmatization of controlled 
medicines because of the use of inappropriate terminology. Confusion and discrimination relating 
to terminology can deter doctors from prescribing controlled medicines when it is legitimate to do 
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so; it can also confuse authorities who wish to discriminate between legitimate and illegitimate 
use. Countries should therefore take steps to review policies to ensure the consistent use of medical 
terms and remove stigmatizing terminology from their legislation. These guidelines specifically 
recommend the use of non-stigmatizing terminology.
Confusion may occur between “abuse” (or “misuse”) on the one hand , and long-term medical use 
on the other. The 1961 and 1971 Conventions do not define the terms “misuse” or “abuse”. However, 
“abuse” is defined by the WHO Expert Committee on Drug Dependence as “persistent or sporadic 
excessive drug use inconsistent with or unrelated to acceptable medical practice” (1). This definition 
excludes the long-term use of controlled medicines concurrent with rational medical practice. 
A further confusion relates to the definition of “dependence” and “dependence syndrome”. Reference 
is also made to the glossary. The WHO definition of “dependence syndrome” requires the presence 
of at least three out of six symptoms, including a strong desire or a sense of compulsion to take 
the drug and also the neglecting of interests and daily activities because of devotion to the use of 
psychoactive substances. It is clear that a patient requiring increasing doses of an opioid for pain 
relief because of pharmacological tolerance due to prolonged treatment does not normally fall into 
this category. Neither does a patient who develops withdrawal syndrome.
Furthermore, it is recommended to avoid the use of stigmatizing terms like “dangerous drugs”, 
“addiction”, etc. for controlled medicines in legislation. Distinction should be made between the 
legal terms “narcotic drugs” and “psychotropic drugs” referring to substances controlled under both 
conventions, and medicine classes such as opioid analgesics, long-acting opioid agonists, etc. 
Patients should be referred to in a respectful way; WHO does not therefore recommend the use of 
“addict” for a patient living with dependence syndrome, as the term is considered to be stigmatizing. 
healthcare professionals
 GuIdelIne 11 
Appropriately trained and qualified physicians, and, if applicable, nurses and other health 
professionals, at all levels of health care should be allowed to prescribe and administer 
controlled medicines, based on their general professional license, current medical 
knowledge and good practice without any further license requirements. 
All healthcare professionals should be trained appropriately for the professional activities they 
actually perform, and this applies equally to the prescription of controlled medicines. The 
competence to prescribe controlled medicines, including strong opioids, should not be restricted 
to a small number of medical specialties, e.g. oncologists only, and controlled medicines should be 
available at all appropriate levels of care. 
Requirements for physicians to obtain a license for prescribing controlled substances may lead 
to limited access and availability (see also Guideline 6). In all countries, all physicians should be 
sufficiently trained to treat pain and hence be allowed to prescribe opioid analgesics if necessary. 
Training for treatment of other conditions depends on whether a condition occurs or not within 
their specialty. 
In some countries, other healthcare workers, such as nurses, can specialize in a specific area and 
are then allowed to prescribe within the area of their specialization as well. Nurse prescribing can 
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be useful e.g. for mitigating pain in a number of circumstances; for example, during a shortage of 
physicians or to improve the quality of care. 
When balancing drug control legislation and policies, it is wise to leave medical decisions up to 
those who are knowledgeable on medical issues. Therefore, the amount of medicine prescribed, 
the appropriate formulation and the duration of treatment should be the practitioner’s decision, 
based on individual patient needs and on sound scientific medical guidance (e.g. national or WHO 
treatment guidelines). An example of how this rule may sometimes be violated is the legal restriction 
on the maximum daily dosage of strong opioids. Another example is the limitation of the use of 
strong opioids only to certain conditions such as cancer pain or terminal cancer pain, while other 
moderate to severe pain remains unaddressed.
Relevant international law and principles
Single Convention, Article 30, paragraph 2 (b): “[Governments shall] ... (i) Require medical prescriptions for the supply or 
dispensation of drugs to individuals. This requirement need not apply to such drugs as individuals may lawfully obtain, 
use, dispense or administer in connection with their duly authorized therapeutic functions; and (ii) If the Parties deem 
these measures necessary or desirable, require that prescriptions for drugs in Schedule I should be written on official forms 
to be issued in the form of counterfoil books by the competent governmental authorities or by authorized professional 
associations” (see also under Guideline 6).
 GuIdelIne 12 
Appropriately trained and qualified pharmacists at all levels of health care should be 
allowed to dispense controlled medicines, based on their general professional license, 
current medical knowledge and good practice without any further license requirements.
As the need for controlled medicines can be present at all levels of health care, all pharmacists 
should be trained appropriately for the dispensing of these medicines. Requirements for pharmacists 
to obtain a license for prescribing controlled substances may limit access and availability (see also 
Guideline 6). 
Some countries allow for the correction of technical errors by pharmacists. In order to start the 
prescribed therapy in a timely manner, legislation should address the pharmacist’s ability to correct 
technical errors in prescriptions and to dispense small amounts of controlled medicines in case of 
emergencies.
Paragraph 43 of the INCB special report of 1989, states: “While sanctions are necessary to deal 
with persons who transgress the law, they should not, as such, constitute an impediment to the 
prescription or dispensation of opiates in accordance with existing regulations. The vast majority 
of health professionals exercise their activity within the law and should be able to do so without 
unnecessary fear of sanctions for unintended violations. Occasions may still arise when a health 
professional could nevertheless be exposed to legal action for technical violations of the law. This 
possibility may tend to inhibit the prescribing or dispensing of opiates.”
Relevant international law and principles
The Convention on Psychotropic Substances, Article 9, paragraph 3 permits that countries allow authorized licensed 
pharmacists or other licensed retail distributors to supply, at their discretion and without prescription, for use for medical 
purposes by individuals in exceptional cases, small quantities of substances in Schedules III and IV: “Notwithstanding 
paragraph 1, a Party may, if in its opinion local circumstances so require and under such conditions, including record-
keeping, as it may prescribe, authorize licensed pharmacists or other licensed retail distributors designated by the 
authorities responsible for public health in its country or part thereof to supply, at their discretion and without 
prescription, for use for medical purposes by individuals in exceptional cases, small quantities, within limits to be defined 
by the Parties, of substances in Schedules III and IV.”
The drug control conventions provide no guidance on correction of errors in prescriptions by pharmacists. 
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 GuIdelIne 13 
Governments should promote that medical, pharmaceutical and nursing schools teach the 
knowledge and skills for the treatment of pain, substance use disorders in the context of 
medical use of controlled medicines, and other health conditions that need treatment with 
controlled medicines.
In all countries, including those where the use of controlled medicines is not yet common, it 
is important that all healthcare schools teach their use. Although controlled medicines and in 
particular strong opioids can be applied safely, basic knowledge is essential and an opportunity to 
practice their application under supervision of an experienced peer is important. In its 2006 annual 
report, the INCB encouraged all Governments to ensure that “the rational use of narcotic drugs and 
psychotropic substances for medical purposes and the risks associated with drug abuse are included 
… in university curricula” (17).
Current best practices should be derived from WHO treatment guidelines and other international 
and national evidence-based guidelines for the various diseases that need treatment with controlled 
medicines. Annex 2 lists a selection of WHO guidelines related to treatment with controlled 
medicines.
Relevant international law and principles
Under both conventions, there is an obligation to the countries to “promote the training of personnel in the treatment 
... of abusers of drugs … as far as possible”. k (Single Convention, Article 38, paragraph 2; the Convention on Psychotropic 
Substances, Article 20, paragraph 2 has almost identical wording).
General Comment 14, (paragraph 12 (a): “[The right to health...contains the following…elements...] Functioning public 
health and health-care facilities, goods and services, as well as programmes, have to be available in sufficient quantity 
within the State party. The precise nature of the facilities, goods and services will vary depending on numerous factors, 
including the State party’s developmental level. They will include, however, the underlying determinants of health, such as 
... trained medical and professional personnel receiving domestically competitive salaries.”
Paragraph 35: “The right to health, like all human rights, imposes three types or levels of obligations on States parties: the 
obligations to respect, protect and fulfil (paragraph 33)”. “Obligations to protect include, inter alia, the duties of States 
to ... ensure that medical practitioners and other health professionals meet appropriate standards of education, skill and 
ethical codes of conduct.” 
 GuIdelIne 14 
In countries where controlled medicines become available and accessible for the first time, 
governments should organize education initiatives for healthcare professionals to ensure 
their rational use.
It is important while introducing policies on accessibility and availability of controlled medicines 
to provide the relevant healthcare staff with the knowledge and skills for using these medicines 
appropriately; training courses should therefore be provided throughout the country. This also 
applies to some degree when a new substance becomes available or a new indication is approved. 
k Remark on the word “abusers”: note that dependence is a disorder that needs treatment, occasional abuse is not necessarily a 
disorder, as can be concluded from the ICD-10 criteria described under Guideline 10 and in the glossary.
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estimates and statistics
 GuIdelIne 15 
Governments should develop a practical method to estimate realistically the medical and 
scientific requirements for controlled substances, using all relevant information.
 GuIdelIne 16 
Governments should furnish to the INCB estimates and assessments of the quantities of 
controlled substances required for legitimate medical and scientific purposes (estimates 
annually for narcotic drugs and certain precursors; assessments at least every three years 
for psychotropic substances). Governments should furnish supplementary estimates or 
modified assessments to the INCB if it appears that the availability of controlled substances 
for legitimate purposes will fall short because of initial underestimation of regular demand, 
emergencies or exceptional demand.
The Single Convention provides for a system of estimates of requirements for narcotic drugs that 
enables INCB, in cooperation with governments, to support the balance between the supply of 
and demand for these drugs. The system allows countries to manufacture and/or import narcotic 
drugs provided that the total estimated amount is not exceeded, and prevents from manufacturing 
and/or importing more narcotic drugs than required for legitimate purposes, which could lead 
to the diversion of the excess to illicit markets. During the course of a year, governments can 
submit supplementary estimates at any time. Governments should establish estimates using the 
recommendations and methods proposed by WHO and INCB. These methods recommend including 
a certain surplus amount in order to minimize chances that the estimates prove to be insufficient 
towards the end of the year.
While no such system is foreseen for psychotropic substances by the 1971 Convention, a system 
of assessments (simplified estimates) was established by Economic and Social Council Resolutions 
1981/7 and 1991/44. By adopting Resolution 49/3, the Commission on Narcotic Drugs requested 
governments to also provide INCB with estimates of their legitimate requirements for certain 
precursors frequently used in the manufacture of amphetamine-type stimulants.
Relevant international law and principles
Single Convention, Article 19, paragraph 1: “The Parties shall furnish to the Board each year for each of their territories, 
in the manner and form prescribed by the Board, estimates on forms supplied by it in respect of the following matters: 
(a) Quantities of drugs to be consumed for medical and scientific purposes; (b) Quantities of drugs to be utilized for the 
manufacture of other drugs, of preparations in Schedule III, and of substances not covered by this Convention; (c) Stocks 
of drugs to be held as at 31 December of the year to which the estimates relate”. 
Single Convention, Article 19, paragraph 4: “The Parties shall inform the Board of the method used for determining 
quantities shown in the estimates and of any changes in the said method”. 
Single Convention, Article 12, paragraph 3: “If any State fails to furnish estimates in respect of any of its territories by the 
date specified, the Board shall, as far as possible, establish the estimates. The Board, in establishing such estimates, shall to 
the extent practicable do so in co-operation with the Government concerned.” 
Single Convention, Article 12, paragraph 5. “The Board, with a view to limiting the use and distribution of drugs to 
an adequate amount required for medical and scientific purposes and to ensuring their availability for such purposes, 
shall as expeditiously as possible confirm the estimates, including supplementary estimates, or, with the consent of the 
Government concerned, may amend such estimates”. 
Single Convention, Article 21, paragraph 4 (b): “Parties shall not during the year in question authorize any further exports 
of the drug concerned to that country or territory, except: (i) In the event of a supplementary estimate being furnished 
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for that country or territory in respect both of any quantity over imported and of the additional quantity required, or 
(ii) In exceptional cases where the export, in the opinion of the Government of the exporting country, is essential for the 
treatment of the sick”.
 GuIdelIne 17 
Governments are required to submit statistical reports to the INCB on narcotic drugs and 
psychotropic substances in accordance with the respective provisions of the international 
drug control conventions and relevant resolutions of the Economic and Social Council. 
Besides having to submit estimates and assessments in advance, countries also have to report to the 
INCB on actual activities involving controlled substances, such as their production, manufacture, 
import and export, utilization, consumption and stocks. The reporting requirements for narcotic 
drugs are more detailed than for psychotropic substances. Statistics are useful for the national 
competent authority, the INCB and others to evaluate, inter alia, the consumption levels of narcotic 
drugs and psychotropic substances, the quality of previous estimates and assessments and the 
methods to establish them, as well as to evaluate and improve the quality of accessibility and 
availability of controlled medicines, their supply and the services using them.
The conventions and resolutions require that reports be submitted by the national competent 
authorities to the INCB, including quarterly statistics of imports and exports of narcotic drugs; 
quarterly statistics of imports and exports of psychotropic substances in Schedule II of the 1971 
Convention; annual statistics of narcotic drugs; and annual statistics of psychotropic substances. 
Quarterly reports have to be furnished four times a year by the end of the month following the 
quarter to which they relate, while annual reports have to be submitted by 30 June following the 
year to which they relate.
Relevant international law and principles
Single Convention, Article 20, paragraph 1: “The Parties shall furnish to the Board for each of their territories, in the 
manner and form prescribed by the Board, statistical returns on forms supplied by it in respect of the following matters: 
a) Production or manufacture of drugs; 
b) Utilization of drugs for the manufacture of other drugs, of preparations in Schedule III and of substances not covered by 
this Convention, and utilization of poppy straw for the manufacture of drugs; 
c) Consumption of drugs; 
d) Imports and exports of drugs and poppy straw; 
e) Seizures of drugs and disposal thereof; 
f) Stocks of drugs as at 31 December of the year to which the returns relate; and
g) Ascertainable area of cultivation of the opium poppy.”
Convention on Psychotropic Substances, Article 16, paragraph 4: “The Parties shall furnish to the Board annual statistical 
reports in accordance with forms prepared by the Board: 
a) In regard to each substance in Schedules I and II, on quantities manufactured, exported to and imported from each 
country or region as well as on stocks held by manufacturers; 
b) In regard to each substance in Schedules III and IV, on quantities manufactured, as well as on total quantities exported 
and imported; 
c) In regard to each substance in Schedules II and III, on quantities used in the manufacture of exempt preparations; and 
d) In regard to each substance other than a substance in Schedule I, on quantities used for industrial purposes in 
accordance with sub-paragraph b) of article 4. 
The quantities manufactured which are referred to in sub-paragraphs a) and b) of this paragraph do not include the 
quantities of preparations manufactured.”
34
Procurement
 GuIdelIne 18 
Governments should ensure, in cooperation with companies and agencies managing 
distribution, that the procurement, manufacture, and distribution of controlled medicines 
are accomplished in a timely manner with good geographical coverage so that there are no 
shortages of supply, and that such medicines are always available when they are needed 
while maintaining adequate controls to prevent diversion, abuse, or dependence syndrome. 
As part of a government’s obligation to ensure the adequate availability and accessibility of 
controlled medicines, it is essential that the procurement, manufacturing and distribution of these 
substances are well organized. This is based on the assumption that there is a list of controlled 
medicine formulations which received marketing authorization within the country. The WHO Model 
List of Essential Medicines and the WHO Model List of Essential Medicines for Children can serve as a 
model to determine a minimum set of medicines for which substances and dosage forms are needed 
(Annex 1) (84, 90).
The provision of adequate availability of controlled medicines is part of a country’s obligation under 
international treaties and subject to monitoring by INCB. 
Similar to any other medicine, a controlled medicine needs to be in stock in order for it to be 
continuously dispensed, as interruption of supply will also interrupt the patients’ treatment. Such 
interruption may entail serious consequences for patients.
Abrupt discontinuation of treatment with opioid analgesics may cause the return of the patient’s 
pain (if the underlying cause continues to be present) and withdrawal syndrome, with symptoms 
including hypertension, nausea and vomiting, painful abdominal cramps, diarrhoea and muscle pain. 
In the case of interruption of treatment with long-acting opioid agonists for dependence syndrome, 
the interruption may also cause withdrawal syndrome. Patients with dependence syndrome are 
familiar with this syndrome and know that it can be treated with (illicit) opioids. In such a case they 
may drop out of the programme and relapse. Periods without access to medication compromise the 
results from prolonged periods of programmes for dependence treatment and HIV prevention. 
With regards to the occurrence of withdrawal syndrome, it should be noted that this is not 
necessarily a sign that patients have dependence or dependence syndrome as explained under 
Guideline 10. Withdrawal syndrome can usually be avoided by gradually decreasing the dosage. For 
other controlled medicines, interruption poses serious problems for patients, whether the return of 
epileptic seizures, psychiatric crises, or maternal death (in case of unavailability of ergometrine and 
ephedrine). 
If controlled medicines are to be accessible at the appropriate level of health care (please see 
explanation under Guideline 7), there is a requirement for them to be widely available in pharmacies 
and at the required health services. Almost all controlled medicines are also used at the primary care 
level and their availability should not therefore be solely limited to hospital pharmacies. Patients 
and their families should not need to incur high costs in terms of travel time and money in order to 
reach pharmacies dispensing controlled medicines. 
Preferably, the distribution of controlled medicines should be combined with that of other non-
controlled medicines through reliable medicine distribution systems. A state monopoly on controlled 
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medicines is not required by the conventions and will, in many cases, pose additional barriers for 
accessibility and availability of these medicines. This is often the case where a state monopoly 
coincides with the centralization of delivery; for example, where delivery is limited to one location in 
the nation’s capital or to a limited number of locations in provincial capitals, or where pharmacists 
need to appear in person to collect their order for controlled medicines.
Relevant international law and principles
Guideline 18 is a consequence of Guidelines 2 and 7. Also other Guidelines are related (e.g. 8, 9, 11, 12, 15, 16 and 17). 
Relevant international law is presented under these Guidelines.
 GuIdelIne 19 
Governments should minimize the negative impact of control and safety measures on the 
affordability and availability of controlled medicines. 
On the world market, morphine and methadone are relatively cheap substances and many other 
opioid raw materials are also relatively inexpensive. Yet although drugs as such are not expensive, 
they may be restricted as a result of safety measures, and in many countries there are control 
measures that affect pricing. Many of these measures are not required in the conventions and are 
not necessary to prevent diversion. 
The challenge for many countries with current low consumption of controlled medicines is to 
make and keep them affordable during the period of transition to better access and availability. 
In situations with low turnover, the cost of licenses and registration can prove prohibitive for 
marketing these medicines. In production and distribution, the cost of packing a batch of 100 tablets 
is not much different from packing a batch of 10 000 tablets and the same is true for the cost of 
transportation. A pharmacy that is required to make high investments in safety measures in order to 
be allowed to dispense controlled medicines may decide not to procure and stock them; these factors 
can make controlled medicines artificially expensive and may be a barrier to increased consumption. 
Countries should perform a review of their control and safety measures and the impact on controlled 
medicines pricing. In particular, attention should be paid to ensuring that any safety measure and 
the cost related to that measure is proportional to the actual risk of diversion. Countries should take 
adequate steps to remedy any problems found. 
Relevant international law and principles
Guideline 19 is a consequence of Guidelines 2 and 7. Also other Guidelines are related (e.g. 8, 9, 11, 12, and 18). Relevant 
international law is presented under these Guidelines.
 GuIdelIne 20 
Drug control authorities should be aware of the existence of the WHO model guidelines 
for the international provision of controlled medicines for emergency medical care, which 
provide a simplified procedure for importation and exportation of controlled medicines into 
a country where disaster disrupted the functioning of the drug control authorities. They 
should apply them when necessary.
Both natural and man-made disasters can cause an increased demand for controlled substances, 
but can also disrupt national drug control authorities and result in them not being able to issue 
import licenses for controlled medicines. The INCB, in its report for 1994, recommended that control 
obligations could be limited to the authorities of exporting countries in emergency situations (15). 
This principle was endorsed at the UN Commission on Narcotic Drugs and the World Health Assembly 
(91, 92).
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When such a disaster situation occurs, other competent authorities should be aware that the WHO 
model guidelines for the international provision of controlled medicines for emergency medical care 
may be applicable (15). These model guidelines assist national authorities with simplified regulatory 
procedures. In cases where there is doubt in relation to their applicability, it is recommended that the 
International Narcotics Control Board is consulted.
Relevant international law and principles
The general principle from the international drug control conventions is that controlled medicines are indispensable and 
that adequate provision must be made to ensure their availability. (See under Guideline 1 for the text of the conventions’ 
preambles).
General Comment 14, paragraph 40: “States parties have a joint and individual responsibility, in accordance with the 
Charter of the United Nations and relevant resolutions of the United Nations General Assembly and of the World Health 
Assembly, to cooperate in providing disaster relief and humanitarian assistance in times of emergency”.
other
 GuIdelIne 21 
Governments that decide to bring medicines under national control that are not controlled 
under the international drug control conventions should apply these guidelines equally to 
those nationally controlled medicines.
At times, governments may feel compelled to bring substances that are not internationally 
controlled under national control if they are perceived to pose serious risk of misuse and harm to 
public health. Under the international drug conventions, countries have the authority to do so. Yet, 
where such decisions concern substances that are also medicines - and particularly when they are 
essential medicines - and thus may have a significant impact on the availability and accessibility of 
these substances for medical and scientific uses, they must be made only with restraint and care. 
If governments do decide to consider national scheduling, they should do so only after a careful and 
transparent process involving all relevant stakeholders that weighs the costs and benefits of such 
step. In particular, they should examine:
 ‣ the evidence of risk of hazardous and harmful use; 
 ‣ the extent of the threat for public health and society;
 ‣ the significance of the substance for medical care;
 ‣ the impact on availability and accessibility of scheduling the substance.
Before deciding whether the substance should be scheduled or not, governments should take into 
account a scientific assessment of its dependence liability by WHO’s Expert Committee on Drug 
Dependence, if available.l
If a government decides that both the risk of hazardous and harmful use and the threat for public 
health and society are so significant that national scheduling is appropriate, it should develop and 
implement a plan of action with guidelines that are capable of ensuring that the availability and 
accessibility of the substance for medical and scientific purposes is not interrupted after scheduling 
or negatively affected over time. 
l For all documentation related to the Expert Committee on Drug Dependence, please see: http://www.who.int/medicines/areas/
quality_safety/ECDD/en (accessed 9 January 2011). 
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The above recommendations are particularly important given the fact that, for example, the national 
scheduling of ketamine and tramadol has led to reduced availability and accessibility of these 
medicines in many countries. Ketamine is an essential medicine used for anesthesia in resource-poor 
settings and is frequently the only anesthetic available for surgery. Tramadol is a weak opioid that 
is used in many countries to manage moderate pain, reviewed by the 34th WHO Expert Committee 
on Drug Dependence in 2006. The Committee “considered that, even after recent major increase in 
the extent of its use because of its therapeutic usefulness, tramadol continues to show a low level 
of abuse. Hence the Committee concluded that there was not sufficient evidence to justify a critical 
review”. National scheduling has resulted in reports of unavailability of these medicines, with serious 
consequences for patients (93, 94).
Relevant international law and principles




m A version in Word format is available on the enclosed CD-ROM.
Governments and other interested groups, including healthcare professionals, may use the following checklist 
to guide their analysis of national drug control policies and the extent to which the guidelines are adhered to 
in their country. At the country level, it may be a taskforce or working group that may be put in charge of this 
task. Please note that some further enquiry may be required prior to answering the questions contained in this 
checklist. 
The numbering of the 67 questions corresponds with the numbering of the guidelines. In some cases a question 
may refer to more than one guideline; in such a case its number refers to the most relevant guideline. For each 
question, the checklist indicates whether it is a question on legal issues (“L”: 11 questions), policy issues (“P”: 53 
questions) or both (“L/P”: 3 questions). This may enhance assessment by teams who want to split their work over 
both policy and legal sub-teams.
For most questions, the answer that is most favourable for ensuring good access and availability to controlled 
medicines is represented in bold. Thus, for any question where the answer is not presented in bold, there is 
an opportunity to work on improvement. By working systematically on these issues, a country can gradually 
improve access and availability of controlled medicines. A systematic approach also necessitates completion of 
the Country Assessment Checklist at a later date.
 













1 L/P Is there a provision in the legislation or in official national 
policy documents that controlled medicines are absolutely 
necessary for medical and pharmaceutical care?




2 P Is there a provision in the legislation that establishes the 
government’s obligation to make adequate provision to ensure:
	‣ the availability of controlled medicines for medical and 
scientific purposes, including the relief of pain and suffering?




	‣ the prevention and treatment of substance dependence?




3 P Has the government established a national authority for 
implementing the obligation to ensure adequate availability 
of controlled medicines for medical and scientific purposes, 
including licensing, estimates and statistics?


















4 P a) Is there a mechanism (such as a regular meeting) among 
government agencies to coordinate drug control policies and 
to concert all sub-policies?
	 yes, please describe mechanism:  




4 P b) Does the mechanism involve the agencies responsible for 
the following functions:
	‣ drug control legislation?




	‣ anti-drug diversion policies?




	‣ healthcare policies (pharmaceutical, cancer, HIV policies, 
etc.)?
































4 P c) Does the mandate of the mechanism involve:
	‣ the promotion of the availability and accessibility of 














5 P a) Is there a mechanism for cooperation between the 
government and healthcare professionals to ensure the 
availability and accessibility of controlled medicines for 
medical and scientific purposes, including for the relief of pain, 
treatment of opioid dependence and other medical illness, as 
well as the prevention of abuse, dependence and diversion?




5 P b) Does the cooperation involve the agencies responsible for 
the following functions:
	‣ drug control legislation?




	‣ anti-drug diversion policies?

















	‣ healthcare policies (pharmaceutical, cancer, HIV policies, 
etc.)?
























	‣ representatives of health professionals?




	‣ representatives of patients?




	‣ representatives of health insurances?

















5 P c) Does the mandate of the cooperation involve:
	‣ the promotion of the availability and accessibility of 















5 P d) Does the cooperation comprise the following aspects
	‣ to assist the needs assessment for controlled medicines 











	‣ implementation of best practices, development of national 

























	‣ to advise on improving prevention and control of 
substance abuse and dependence without establishing new 





6 P Did the government make adequate provision to ensure 
education of government officers and others whose work 
requires an understanding of the problems of abuse of drugs 
and of its prevention, including the relation to health policies 
and legitimate treatment with controlled medicines?




Policy planning for availability and accessibility
National medicines policy plan: 
7 P a1) Is there an approved national medicines policy plan 
that includes the availability and accessibility of controlled 
medicines for all relevant medical and scientific uses?
	 yes, please reference: 




7 P a2) Does the national medicines policy plan (or any 
government policy) make provision for a List of Essential 
Medicines, modeled after the WHO Model List of Essential 
Medicines and the WHO Model List of Essential Medicines for 
Children?




7 P a3) Does this List of Essential Medicines include all medicines 
currently on, or equivalent to the controlled medicines on, the 
WHO Model List of Essential Medicines and the WHO Model 
List of Essential Medicines for Children?
	 yes
















7 P a4) Does the national medicines policy plan (or any 
government policy) make provision for policies that address 
the rational use of controlled medicines by the general 
population, including that patients and their families should 
be informed about the treatment of pain and treatment of 
dependence?




7 (P - Refers 
also to 
Guidelines 
11 and 12) 
a5) Does the national medicines policy plan (or any 
government policy) provide for the availability of the relevant 
medicines at appropriate levels of care, including both the 
availability of strong opioid analgesics at all levels and the 
authority of prescribing by all relevant medical specialties?




7 P a6) Does the national medicines policy plan (or any 
government policy) make adequate provision that patients who 
are hospitalized for other reasons are able to continue their 
treatment with controlled medicines?




7 P a7) Does the national medicines policy plan (or any 
government policy) make adequate provision that treatment 
continues for people on controlled medicines when arrested 
or imprisoned, regardless whether they are on pain treatment, 
treatment for dependence or for other diseases?




Disease specific policy plans:
- Cancer:
7 P b1) Is there an approved national comprehensive cancer 
control program that includes access to and availability of 
strong opioid analgesics for treatment of moderate to severe 
pain and for services like hospice and palliative care where 
patients can obtain such treatment?
	 yes, please reference: 

















7 P b2) Has it been verified that no provisions in the policy plan 
granting rights to one patient group could be explained as 





7 P b3) Are sufficient resources available for the implementation 
of the policy?





7 P c1) Is there an approved national HIV/AIDS policy programme 
that:
	‣ includes the treatment of moderate to severe pain through 
availability and accessibility of strong opioid analgesics 
and of services like hospice and palliative care where 
patients can obtain such treatment?




	‣ includes the prevention of HIV transmission through 
availability and accessibility of opioid agonist therapy and 
treatment centers where patients with opioid dependence 
can obtain such treatment?
	 yes, please reference: 




7 P c2) Has it been verified that no provisions in the policy plan 
granting rights to one patient group could be explained as 


















7 P c3) Are sufficient resources available for the implementation 
of the policy?





7 P d1) Is there an approved national mental healthcare 
programme on opioid dependence that includes prevention 
of substance abuse and dependence, treatment of substance 
dependence through availability and accessibility of opioid 
agonist therapy and treatment centers where patients with 
opioid dependence can obtain such treatment?
	 yes, please reference: 




7 P d2) Has it been verified that no provisions in the policy plan 
granting rights to one patient group could be explained as 





7 P d3) Does the mental healthcare programme on opioid 
dependence make adequate provision that treatment 
continues for people on controlled medicines when arrested 
or imprisoned, regardless whether they are on pain treatment, 
treatment for dependence or for other diseases?




7 P d4) Does the mental healthcare programme on opioid 
dependence make adequate provision that prisons have 
functioning treatment programmes for the treatment of opioid 
dependence?

















7 P d5) Are sufficient resources available for the implementation 
of the policy?




- Psychiatric and neurological disorders:
7 P e1) Is there an approved national mental healthcare 
programme on other psychiatric and neurological disorders 
that includes the availability and accessibility of anxiolytics, 
hypnotics and anti-epileptics?
	 yes, please reference: 




7 P e2) Has it been verified that no provisions in the policy plan 
granting rights to one patient group could be explained as 





7 P e3) Are sufficient resources available for the implementation 
of the policy?





7 P f1) Is there an approved national maternal healthcare 
programme that includes the availability and accessibility of 
oxytocin (not-controlled) and/or ergometrine and of ephedrine 
for emergency obstetric care?
	 yes, please reference: 




7 P f2) Has it been verified that no provisions in the policy plan 
granting rights to one patient group could be explained as 


















7 P f3) Are sufficient resources available for the implementation of 
the policy?




8 P a) Has it been verified that the national medicines policy plan 
and the national disease specific policy plans:





	‣ allow for equal access and availability and do not 




















































































































8 P c) Do pregnant and lactating women have equal access to 





9 L a) Has the government conducted an examination to 
determine if there are provisions in the national and lower 
legislation and in the official policies that are stricter than the 
international drug control conventions require?
	 yes, please specify which laws or regulations 
have been checked and which relevant laws and 




9 L b) If such provisions are present, are they necessary or 
desirable for the protection of the public health or welfare and 
do they contribute to a better public health (as composed of 
the availability and accessibility to controlled medicines for 
rational medical use, and the prevention of abuse, diversion 
and dependence)?

















9 L c) If provisions were identified that are not necessary or 
desirable for the protection of the public health or welfare and 
do not contribute to a better public health, were they either 
removed or replaced by alternative ways to provide the same 
level of prevention without posing a barrier to rational medical 
use?








d) In particular, indicate if the legislation or the policies 
contain the following provisions that are stricter than required 
by the drug control conventions that impede prescribing, 
dispensing and distribution for rational medical use:
	‣ is the time span for which controlled medicines may be 
prescribed more limited than for other medicines?
	 yes, please specify maximum duration and 




	‣ is the validity of prescriptions for controlled medicines 
more limited than for other medicines?
	 yes, please specify maximum validity and 




	‣ is the practitioner allowed to determine the appropriate 
pharmacological treatment (choice of medicine, 
formulation, strength, dosage and duration) based on 
individual patient needs and on sound scientific medical 
guidance?
	 yes




	‣ is there a limitation on the use of strong opioids in 
moderate to severe pain to one or more specific diseases 
(e.g. cancer pain), while moderate to severe pain from 
other causes remains unaddressed?

















	‣ is permission required for the patient to render him/her 





	‣ can controlled medicines be prescribed on a single copy of 
regular prescription paper?
	 yes
	no; please specify what is needed and at what cost:
	unknown

	‣ is there a registration of patients treated with opioids for 
opioid dependence?
	 yes 
if yes, please specify if there are any such 
consequences as the refusal of a driver’s license, 
government employment, housing, or denial of 
child custody, that will cause patients not to seek 
treatment;  
if yes, please specify the period for which the 
registration is kept;  
if yes, please specify what warrants are in place that 




	‣ are health workers with general prescribing authority, 
while performing their professional duties, allowed to 






	‣ are pharmacists with general dispensing authority, while 
performing their professional duties, allowed to dispense 


















	‣ is providing information about treatment with and use of 
controlled medicines allowed and can people providing 





10 L a) Is there terminology in the legislation that has the potential 






10 L b) Does a definition of “abuse” (or “misuse”) exclude the long-
term medical use of controlled medicines concurrent with 
accepted medical practice, and is it clear that medical use of 
controlled substances, whether long-term or not, and whether 
adverse drug reactions (including “drug dependence”) occur or 





10 L c) Does a definition of “dependence” require the presence of 
a strong desire or a sense of compulsion to take the drug and 
is it clear from this definition that the mere occurrence of 






10 L d) Does the legislation contain stigmatizing terms for 
controlled medicines, such as the use of the legal terms 
“narcotic drugs” and “psychotropic drugs” for medicines 






10 L e) Does the legislation refer to patients in a respectful way and 
in particular, does it avoid stigmatizing terminology such as 



















11/12 L a) Can health professionals be free from fear of investigation, 
prosecution and disproportionate punishment for minor or 





12 L b) Are pharmacists allowed to correct technical errors in 
prescriptions and to dispense small amounts of controlled 





13 P a) Is there a government policy that urges medical, 
pharmaceutical and nursing schools to teach the medical use 
of controlled medicines, including the use of opioid analgesics 
and pain management?




13 P b) Are relevant WHO treatment guidelines or other 
international or national evidence-based guidelines for the 
various diseases and disorders that need treatment with 
controlled medicines implemented throughout the country, 
including for:
	‣ pain management?




	‣ treatment of opioid dependence?




	‣ prevention of HIV/AIDS?

















	‣ psychiatric and neurological disorders, in particular on the 
use of anxiolytics, hypnotics and anti-epileptics?









14 P If the country is in a transition towards improved access and 
availability of controlled medicines, are training courses for 
physicians, pharmacists and nurses to teach the rational use of 






15 P a) Does the government have a method to realistically 
estimate the medical and scientific requirements for controlled 
substances?




15 P b) Does this method include a certain surplus in order to 
minimize chances that the estimates are insufficient towards 





15 P c) Has the government critically examined this method and 




















15 P Has the government established a satisfactory system to 
collect information about requirements for controlled 
medicines from relevant facilities?




16 P a) Does the government furnish estimates to the INCB of the 
requirements for narcotic drugs and certain precursors for the 
next year in a timely manner?




16 P b) Does the government furnish assessments (simplified 
estimates) to the INCB of the requirements for psychotropic 
substances at least every three years?




16 P c) If it appears that the medical need for narcotic drugs 
(mainly opioid analgesics and long-acting opioid agonists for 
treatment of dependence) will exceed the estimated amount 
that has been confirmed by the INCB, is it government policy 





17 P Does the government submit to the INCB in a timely manner 
the required quarterly and annual statistical reports on 
narcotic drugs and psychotropic substances?


















Procurement (See also the questions for Guideline 7) 
18 P a) Has the government established a satisfactory system that 
ensures, in cooperation with the distribution channels, that 
the procurement, manufacture, and distribution of controlled 
medicines are accomplished in a timely manner so that there 
are no shortages of supply, and that such medicines are always 





18 P b) Is there a sufficiently geographical coverage of pharmacies 
and/or dispensaries all over the country, not limited to hospital 
pharmacies, where patients and their families can obtain 
controlled medicines without spending considerable amounts 






19 P a) Does the government promote the availability of controlled 
medicines at affordable cost?




19 P b) Are there any fees for licenses for the market admission, 
procurement, manufacture, and distribution of controlled 
medicines in addition to those licenses required for medicines 
not under control?




20 P Are the drug control authorities responsible for issuing export 
permits aware of the existence of the WHO model guidelines 
for the international provision of controlled medicines for 
emergency medical care, and did they ever apply them?
	 yes, but not applied


















21 L/P a) If the country considers enacting for any national drug 
control measures on any substance or medicine not under 
international control, is there a procedure to assess the real 
risk of abuse, the harm caused by such abuse, and its medical 
usefulness in decision-making and is it ensured that any drug 
control measure does not affect medical availability and 
accessibility?




21 L/P If the country applies any national drug control measures on 
any substance or medicine not under international control, 
does it equally apply the relevant guidelines from this 





21 P If ketamine and/or tramadol is a controlled substance in 
the country, is medical availability and accessibility ensured 
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annEX 1
Controlled MediCines also listed as WHo essential MediCines or WHo 
essential MediCines for CHildren (95, 96)




buprenorphine not specified not specified used in substance dependence 
programmes
- x







2. (indication under review) 
antidiarrhoeal (symptomatic) 
medicines in adults 
- x
diazepam * injection 5 mg/ml in 2ml 
ampoule
preoperative medication 
and sedation for short-term 
procedures
x x








5 mg/ml in 1 ml 
tube
x -
5 mg/ml in 2 ml 
tube
x x
5 mg/ml in 4 ml 
tube
x x
tablet 2 mg generalized anxiety x x
5 mg 1. generalized anxiety 
2. preoperative medication 
and sedation for short-term 
procedures
x x
10 mg generalized anxiety x x
ephedrine injection 30 mg 
(hydrochloride)/
ml in 1 ml 
ampoule
spinal anaesthesia during 
delivery, to prevent 
hypotension
- x
ergometrine * injection 200 micrograms 
(hydrogen 




lorazepam * parenteral 
formulation
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oral liquid 5 mg/5 ml used in substance dependence 
programmes
- x
10 mg/5 ml - x
midazolam injection 1 mg/ml anticonvulsant/antiepileptic x -






20 mg opioid analgesic x
-







injection 10 mg/ml (sulfate 
or hydrochloride) 
in 1 ml ampoule
1. preoperative medication 






















opioid analgesic x x
30 mg (morphine 
sulfate)
x x

















tablet various strengths: 
15 mg to 100 mg
anticonvulsant/antiepileptic
x x
thiopental powder for 
injection




1 g (sodium salt) 
in ampoule
x x
* The listed medicine should be the example of the class for which there is the best evidence for effectiveness 
and safety.
Remark: Ketamine injection 50 mg (as hydrochloride)/ml in 10ml vial is listed for general anaesthesia. 
Ketamine is not under international control. However, in some countries it is under national control. 
Therefore according to Guideline 21, the guidelines in this document should be equally applied to ketamine 
(95, 96).
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annEX 2
selected Who treatment guidelines 
Pain treatment
World Health Organization. Cancer pain relief with a guide to opioid availability, 2nd ed. Geneva, 1996. 
Available in Chinese, English*p, French*, Russian, Spanish* and Thai*. 
WHO Bookshop: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=15&cod
cch=2247 (accessed 3 January 2011)
Downloadable from the WHO Library at: http://whqlibdoc.who.int/publications/9241544821.pdf 
(accessed 3 January 2011)
World Health Organization. Cancer pain relief and palliative care in children. Geneva, 1998. ISBN 92 4 
154557 7q. Available in Azeri*, Bulgarian*, Chinese, English*, French*, Romanian*, Russian* and Spanish*. 
WHO Bookshop: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=15&cod
cch=459 (accessed 3 January 2011)
Downloadable from the WHO Library at: http://whqlibdoc.who.int/publications/9241545127.pdf 
(accessed 3 January 2011)
World Health Organization. Palliative care: symptom management and end-of-life care: interim guidelines for 
first-level facility health workers. Geneva, 2004. ISBN 978 92 4 159723 2. Available in English* and French*. 
More information at: http://www.who.int/hiv/pub/imai/primary_palliative/en/index.html 
(accessed 3 January 2011)
Downloadable at: http://www.who.int/hiv/pub/imai/genericpalliativecare082004.pdf 
(accessed 3 January 2011)
World Health Organization. WHO treatment guidelines on the pharmacological treatment of persisting pain 
in children with medical illness. Geneva, in preparation; planned 2011. English and various other languages. 
(Will replace Cancer pain relief and palliative care in children.)
 
World Health Organization. WHO treatment guidelines on the pharmacological treatment of persisting pain 
in adults with medical illness. (planned)
(Will replace Cancer pain relief with a guide to opioid availability)
World Health Organization. WHO treatment guidelines on non-persisting pain. (planned)
Treatment of opioid dependence
World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid 
dependence. Geneva, 2009. ISBN 978 92 4 154754 3. English*. 
WHO Bookshop: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=15&
codcch=745 (accessed 3 January 2011)
Downloadable from the WHO Library at: http://whqlibdoc.who.int/publications/2009/9789241547543_
eng.pdf (accessed 3 January 2011)
p Language versions marked with an asterisk are on the enclosed CD-ROM.
q ISBN Numbers refer to English version. For ISBN numbers for other language versions please consult the links provided.
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delivery
World Health Organization. WHO recommendations for the prevention of postpartum haemorrhage. Geneva, 
2007. English*. WHO ref: WHO/MPS/07.06
More information at: http://www.who.int/making_pregnancy_safer/documents/who_mps_0706/en/
index.html (accessed 3 January 2011)
Downloadable from the WHO Library at: http://whqlibdoc.who.int/hq/2007/WHO_MPS_07.06_eng.pdf 
(accessed 3 January 2011)
World Health Organization. WHO guidelines for the management of postpartum haemorrhage and retained 
placenta. Geneva, 2009. ISBN 978 92 4 159851 4. English*; French, Spanish in press. 
WHO Bookshop: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=15&cod
cch=777 (accessed 3 January 2011)
Downloadable from the WHO Library at: http://whqlibdoc.who.int/publications/2009/9789241598514_
eng.pdf (accessed 3 January 2011)
 
World Health Organization, UNFPA, UNICEF, World Bank. Managing complications in pregnancy and 
childbirth: a guide for midwives and doctors. Geneva , 2007. ISBN 92 4 154587 9. Arabic*, English*, French*, 
Indonesian*, Italian*, Khmer*, Portuguese, Russian, Spanish
WHO Bookshop: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=15&cod
cch=541 (accessed 3 January 2011)
Downloadable from the WHO Library at: http://whqlibdoc.who.int/publications/2007/9241545879_eng.pdf 
(accessed 3 January 2011)
neurology (epilepsy)
Dekker PA. Epilepsy: a manual for medical and clinical officers in Africa. WHO, Geneva, 2002 (revised 
edition). English*.
Downloadable from the WHO Library at: http://whqlibdoc.who.int/hq/2002/WHO_MSD_MBD_02.02.pdf 
(accessed 3 January 2011)
Mental Health
World Health Organization. Pharmacological treatment of mental disorders in primary health care. Geneva, 
2010. ISBN 978 92 4 1547697. English, Spanish 
WHO Bookshop: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=15
&codcch=756 (accessed 3 January 2011)
Downloadable from the WHO Library at: http://whqlibdoc.who.int/publications/2009/9789241547697_
eng.pdf (accessed 3 January 2011)
http://whqlibdoc.who.int/paho/2010/9789275331132_spa.pdf (accessed 3 January 2011)

annEX 3
Contents of the Cd-roM Ensuring balance in national 
policies on controlled substances
•	 Reference list to Ensuring balance in national policies on controlled substances: guidance for 
availability and accessibility of controlled medicines
•	 Country Assessment Checklist (version in Word format)
•	 Barriers to opioid analgesic availability test (BOAT) (Adapted version)
•	 WHO model list of essential medicines, 16th ed. Geneva, March 2009. (Multiple languages)
•	 WHO model list of essential medicines for children, 2nd ed. Geneva, March 2009 (Multiple languages)
•	 Full texts of guidelines mentioned in Annex 2; Selected WHO treatment guidelines (Multiple languages)
•	 World Health Organization, Model guidelines for the international provision of controlled medicines for 
emergency medical care. Geneva, 1996. (English and French)
•	 Further reading 
o Access to Controlled Medicines
o Barriers
o Human rights
o Injecting Drug Use
o Logistics
o Maternal mortality
o Pain management 
o Palliative care
International Conventions:
•	 The international drug control conventions, their schedules and their official commentaries (English)r
•	 ICESCR (English, French) and its General Comment 14 (Multiple languages)
•	 WHO Constitution (Multiple languages)
•	 Other conventions that involve access to medicines and to health
o Convention on the Elimination of All Forms of Discrimination against Women (English)
r For other language versions (Arabic, Chinese, French, Russian and Spanish): www.incb.org (accessed 9 January 2011). 
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